APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 8
August 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 8

August 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 8
August 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
JOHNSON AND JOHNSON PHARMACEUTICAL (JOHNSON AND JOHNSON)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
MCNEIL PEDIATRICS (MCNEIL PED)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO BIOTECH PRODUCTS LP (ORTHO BIOTECH)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC (ORTHO MCNEIL JANSSEN)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC (ORTHO MCNEIL JANSSEN)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
PADDOCK LABORATORIES INC (PADDOCK LABS)	PADDOCK LABORATORIES LLC (PADDOCK LLC)
SHIONOGI PHARMA INC (SHIONOGI PHARMA)	SHIONOGI INC (SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001

LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838	14029	14309		
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)		
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)		
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)		
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)		
EXCEPTIONS[1]	89 (0.6%)	89 (0.6%)	89 (0.6%)		
NEW MOLECULAR ENTITIES APPROVED	8	6	8		
NUMBER OF APPLICANTS	752	768	784		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The

application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

>D>		+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Aug	CAHN
		+		250MG	N202379	001	Apr 28, 2011	Apr	NEWA
>A>		+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Aug	CAHN

ACARBOSE

TABLET; ORAL

ACARBOSE

	AB		STRIDES ARCOLAB LTD	25MG	A090912	001	Jul 27, 2011	Jul	NEWA
	AB			50MG	A090912	002	Jul 27, 2011	Jul	NEWA
	AB			100MG	A090912	003	Jul 27, 2011	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

>A>			BUTALBITAL AND ACETAMINOPHEN						
>A>			NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Aug	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	AA		MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
	AA			500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	AA		WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

>D>	AA		WEST WARD	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC
>A>			@ WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	+	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC
>A>			@	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC

SUSPENSION; ORAL

CAPITAL AND CODEINE

>D>	AA		ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC
>A>			@	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA		WATSON LABS	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
>A>			@	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
>D>	AA			300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
>A>			@	300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
>D>	AA			300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
>A>			@	300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
			@ WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003	Jul	DISC
			@	300MG;30MG	A040443	002	Jan 22, 2003	Jul	DISC

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	WATSON LABS FLORIDA	300MG;60MG	A040443	003	Jan 22, 2003	Jul	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		BOCA PHARMA	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Jul	NEWA
	AA	+	MIKART	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Jul	CTEC

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
	AB			300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
	AA			300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
	AB			300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
	AA			300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
	AB			300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
	AA	+	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
	AA			300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
	AA	+		300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
	AA	+		300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC
		@	RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007	May	DISC
		@		500MG;10MG	A040824	001	Aug 16, 2007	May	DISC
		@	RANBAXY LABS LTD	325MG;10MG	A040826	001	Aug 16, 2007	May	DISC
		@		750MG;7.5MG	A040822	001	Aug 16, 2007	May	DISC
>D>	AA		WATSON LABS	500MG;2.5MG	A040123	003	Mar 04, 1996	Aug	DISC
>A>		@		500MG;2.5MG	A040123	003	Mar 04, 1996	Aug	DISC
>D>	AA			500MG;7.5MG	A040123	004	Mar 04, 1996	Aug	DISC
>A>		@		500MG;7.5MG	A040123	004	Mar 04, 1996	Aug	DISC
>D>	AA			650MG;7.5MG	A040123	001	Mar 04, 1996	Aug	DISC
>A>		@		650MG;7.5MG	A040123	001	Mar 04, 1996	Aug	DISC
>D>	AA			650MG;10MG	A040123	002	Mar 04, 1996	Aug	DISC
>A>		@		650MG;10MG	A040123	002	Mar 04, 1996	Aug	DISC
		@	WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003	Jul	DISC
		@		750MG;7.5MG	A040494	001	May 28, 2003	Jul	DISC

LORTAB

	AA		UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

		@	ACTAVIS TOTOWA	500MG;5MG	A040199	001	Dec 30, 1998	Jul	DISC

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

		@	ACTAVIS TOTOWA	325MG;5MG	A040203	001	Mar 15, 1999	Jul	DISC

>D> ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

>D> TABLET; ORAL
>D> PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AA	+	MYLAN	650MG;65MG	A083978	001		Aug	DISC
>A>		@		650MG;65MG	A083978	001		Aug	DISC
		@	VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

		@	XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC

DARVOCET-N 50

		@	XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

		@	CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC
		@		500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
		@	MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC
	AB			650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
>D>	AB		MYLAN	650MG;100MG	A070145	001	Jun 12, 1985	Aug	CRLD
>A>		+		650MG;100MG	A070145	001	Jun 12, 1985	Aug	CRLD
		@	TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
		@	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
		@		650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC
>D>	AB		WOCKHARDT	325MG;50MG	A077677	001	Mar 16, 2007	Aug	DISC
>D>	AB			650MG;100MG	A077677	002	Mar 16, 2007	Aug	DISC
>A>		@	WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007	Aug	DISC
>A>		@		650MG;100MG	A077677	002	Mar 16, 2007	Aug	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

	AB		INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jul	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

>D>	AT		ACTAVIS MID ATLANTIC	2%	A087146	001		Aug	DISC
>A>		@		2%	A087146	001		Aug	DISC

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

		+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	AB		ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997	Aug	DISC
>A>		@		200MG	A074906	001	Aug 26, 1997	Aug	DISC
	AB		MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

CREAM; TOPICAL

ZOVIRAX

		+	VALEANT INTL	5%	N021478	001	Dec 30, 2002	Jul	CAHN

OINTMENT; TOPICAL

ZOVIRAX

		+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Jul	CAHN

TABLET; ORAL

ACYCLOVIR

>D>	AB		ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997	Aug	DISC
>A>		@		400MG	A074870	001	Jun 05, 1997	Aug	DISC
>D>	AB			800MG	A074870	002	Jun 05, 1997	Aug	DISC
>A>		@		800MG	A074870	002	Jun 05, 1997	Aug	DISC

TABLET; ORAL
ACYCLOVIR

AB		MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB			800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

>D>	AP		APP PHARMS	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Aug	CRLD
>A>	AP	+		EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Aug	CRLD
>D>		+	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997	Aug	DISC
>A>		@		EQ 25MG BASE/ML	A074720	001	Apr 22, 1997	Aug	DISC
		@		EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
>D>			ZOVIRAX						
>D>	AP	+	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N018603	001	Oct 22, 1982	Aug	DISC
>A>		@		EQ 500MG BASE/VIAL	N018603	001	Oct 22, 1982	Aug	DISC
>D>	AP	+		EQ 1GM BASE/VIAL	N018603	002	Jun 29, 1989	Aug	DISC
>A>		@		EQ 1GM BASE/VIAL	N018603	002	Jun 29, 1989	Aug	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL
XERESE

>D>	+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	Aug	CAHN
	+		5%;1%	N022436	001	Jul 31, 2009	May	CTNA
>A>	+	VALEANT INTL	5%;1%	N022436	001	Jul 31, 2009	Aug	CAHN

ALBENDAZOLE

TABLET; ORAL
ALBENZA

	+	COREPHARMA	200MG	N020666	001	Jun 11, 1996	Jun	CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

>D>	AN	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995	Aug	DISC
>A>		@	EQ 0.083% BASE	A073533	001	Sep 26, 1995	Aug	DISC
>D>	AN	COBALT LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Aug	CAHN
	AN	RITEDOSE CORP	EQ 0.083% BASE	A077839	001	Dec 16, 2008	Jul	CAHN
>A>	AN	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Aug	CAHN

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC
LASTACAFT

	+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL
ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 5% IN D5-W

>D>								
>D>	AP	HOSPIRA	5ML/100ML;5GM/100ML	A083263	001		Aug	DISC
>A>		@	5ML/100ML;5GM/100ML	A083263	001		Aug	DISC

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@ SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	10MG	A079013	001	Jul 18, 2011	Jul	NEWA
AB	MYLAN	10MG	A079014	001	Jul 18, 2011	Jul	NEWA
AB	SUN PHARMA GLOBAL	10MG	A079057	001	Jul 18, 2011	Jul	NEWA
AB	TEVA PHARMS	10MG	A079056	001	Jul 18, 2011	Jul	NEWA
AB	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011	Jul	NEWA

UROXATRAL

AB	+ SANOFI AVENTIS US	10MG	N021287	001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM

AP	+ MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Jul	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May	NEWA
AB		1MG	A090871	002	Jun 07, 2011	May	NEWA
AB		2MG	A090871	003	Jun 07, 2011	May	NEWA
AB		3MG	A090871	004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL
MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	May	CAHN
		0.25MG	N020700	002	Nov 19, 1996	May	CAHN
		0.5MG	N020700	003	Nov 19, 1996	May	CAHN
+		1MG	N020700	004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

	@ ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006	Jul	DISC

AMIKACIN SULFATE

INJECTABLE; INJECTION

>D>	AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
>D>	HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997	Aug		DISC
>A>	@	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997	Aug		DISC

AMINO ACIDS

INJECTABLE; INJECTION

>D>	NOVAMINE 11.4%							
>D>	+ HOSPIRA	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982	Aug		DISC
>A>	@	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982	Aug		DISC
>D>	NOVAMINE 15%							
>D>	+ HOSPIRA	15% (15GM/100ML)	N017957	004	Nov 28, 1986	Aug		DISC
>A>	@	15% (15GM/100ML)	N017957	004	Nov 28, 1986	Aug		DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

>D>	AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
>D>	HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;2 05MG/100ML	N019683	001	Nov 07, 1988	Aug		DISC
>A>	@	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;2 05MG/100ML	N019683	001	Nov 07, 1988	Aug		DISC
>D>	AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988	Aug		DISC
>A>	@	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988	Aug		DISC
>D>	AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988	Aug		DISC
>A>	@	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988	Aug		DISC

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

>D>	AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER							
>D>	HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988	Aug		DISC
>A>	@	3.5%;25GM/100ML	N019681	001	Nov 01, 1988	Aug		DISC
>D>	AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988	Aug		DISC
>A>	@	3.5%;5GM/100ML	N019681	002	Nov 01, 1988	Aug		DISC
>D>	AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988	Aug		DISC
>A>	@	4.25%;10GM/100ML	N019681	004	Nov 01, 1988	Aug		DISC
>D>	AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988	Aug		DISC
>A>	@	4.25%;20GM/100ML	N019681	005	Nov 01, 1988	Aug		DISC
>D>	AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988	Aug		DISC
>A>	@	4.25%;25GM/100ML	N019681	003	Nov 01, 1988	Aug		DISC
>D>	AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER							
>D>	HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988	Aug		DISC

INJECTABLE; INJECTION

>D>	AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER							
>A>	@ HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988	Aug	DISC	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

>D>	AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988	Aug	DISC	
>A>	@	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988	Aug	DISC	
>D>	AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER							
>D>	HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988	Aug	DISC	
>A>	@	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988	Aug	DISC	

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN	
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN	
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN	
	@ GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007	Jul	DISC	
	@	EQ 5MG BASE	A077333	002	Jul 17, 2007	Jul	DISC	
	@	EQ 10MG BASE	A077333	003	Jul 17, 2007	Jul	DISC	
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Mar	NEWA	
AB		EQ 5MG BASE	A077771	002	Apr 12, 2011	Mar	NEWA	
AB		EQ 10MG BASE	A077771	003	Apr 12, 2011	Mar	NEWA	
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	May	CAHN	
AB		EQ 5MG BASE	A078131	002	Sep 04, 2007	May	CAHN	
AB		EQ 10MG BASE	A078131	003	Sep 04, 2007	May	CAHN	
AB	SECAN PHARMS	EQ 5MG BASE	A090752	001	Apr 15, 2011	Apr	NEWA	
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Apr	NEWA	

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011	Jun	NEWA	
AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011	Jun	NEWA	
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011	Jun	NEWA	
AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	Jun	NEWA	
AB	MYLAN	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Jun	NEWA	
AB		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Jun	NEWA	
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun	NEWA	
AB		EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun	NEWA	
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011	Jun	NEWA	
AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011	Jun	NEWA	

LOTREL

AB	NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG	
AB +		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR	
AB		500MG	A062058	002		Feb	CDFR	

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

>A>		+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008	Aug	CAHN
>D>		+	VICTORY PHARMA	775MG	N050813	001	Jan 23, 2008	Aug	CAHN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

>D>	AB		RANBAXY	200MG	A065080	002	Aug 11, 2003	Aug	DISC
>D>	AB	+		400MG	A065080	001	Aug 11, 2003	Aug	DISC
>A>			@ RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003	Aug	DISC
>A>			@	400MG	A065080	001	Aug 11, 2003	Aug	DISC

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

		+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

	AP	+	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD

FUNGIZONE

			@ APOTHECON	50MG/VIAL	A060517	001		Jun	DISC

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

		+	ALDOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Jul	CAHN
		+		100MG/VIAL	N050729	002	Nov 22, 1996	Jul	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

	AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
	AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
	AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
	AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
	AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

			DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul	CTEC

PRINCIPEN

			@ APOTHECON	EQ 125MG BASE/5ML	A061394	002		Jul	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN
	AB		SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Jul	NEWA
			@ SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010	Jul	DISC

ARGATROBAN

INJECTABLE; IV (INFUSION)
ARGATROBAN IN SODIUM CHLORIDE

		+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Jun	NEWA
		+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)
ARGATROBAN IN DEXTROSE

		@	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	May	DISC

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS

>A>		+	MERCK SHARP DOHME	EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN
>D>		+	ORGANON USA INC	EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AA		ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983	Aug	DISC
>A>		@		325MG;50MG;40MG	A086710	002	Aug 23, 1983	Aug	DISC
		@	PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983	Jun	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

	AB		MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
	AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

	AB		MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
	AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ASPIRIN

	AA		COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA
	AA		WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA

PERCODAN

	AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL
ATENOLOL

	AB		MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
	AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
	AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

>D>	AB		ACTAVIS ELIZABETH	10MG	A078940	001	Aug 30, 2010	Aug	DISC
>A>		@		10MG	A078940	001	Aug 30, 2010	Aug	DISC
>D>	AB			18MG	A078940	002	Aug 30, 2010	Aug	DISC

CAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

>A>		@ ACTAVIS ELIZABETH	18MG	A078940	002	Aug 30, 2010	Aug	DISC
>D>	AB		25MG	A078940	003	Aug 30, 2010	Aug	DISC
>A>		@	25MG	A078940	003	Aug 30, 2010	Aug	DISC
>D>	AB		40MG	A078940	004	Aug 30, 2010	Aug	DISC
>A>		@	40MG	A078940	004	Aug 30, 2010	Aug	DISC
>D>	AB		60MG	A078940	005	Aug 30, 2010	Aug	DISC
>A>		@	60MG	A078940	005	Aug 30, 2010	Aug	DISC
>D>	AB		80MG	A078940	006	Aug 30, 2010	Aug	DISC
>A>		@	80MG	A078940	006	Aug 30, 2010	Aug	DISC
>D>	AB		100MG	A078940	007	Aug 30, 2010	Aug	DISC
>A>		@	100MG	A078940	007	Aug 30, 2010	Aug	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

	AB	GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

	AB	+ GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

ATROPINE

INJECTABLE; INJECTION
ATROPINE

		@ SOLVAY	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Jul	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL
ASTEPRO

>D>								
>D>		+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Aug	DISC
>A>		@	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Aug	DISC

AZILSARTAN MEDOXOMIL

TABLET; ORAL
EDARBI

		TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
		+	80MG	N200796	002	Feb 25, 2011	Feb	NEWA

AZITHROMYCIN

TABLET; ORAL
AZITHROMYCIN

	AB	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Jul	NEWA
	AB		EQ 500MG BASE	A065509	001	Jul 13, 2011	Jul	NEWA
	AB		EQ 600MG BASE	A065508	001	Jul 13, 2011	Jul	NEWA

AZTREONAM

INJECTABLE; INJECTION
AZTREONAM

	AP	BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
	AP		2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

		+ FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
		+ NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
	+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

>A>	AB	PRINSTON INC	5MG	A076118	001	Feb 11, 2004	Aug	CAHN
>A>	AB		10MG	A076118	002	Feb 11, 2004	Aug	CAHN
>A>	AB		20MG	A076118	003	Feb 11, 2004	Aug	CAHN
>A>	AB		40MG	A076118	004	Feb 11, 2004	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	5MG	A076118	001	Feb 11, 2004	Aug	CAHN
	AB		5MG	A076118	001	Feb 11, 2004	May	CAHN
>D>	AB		10MG	A076118	002	Feb 11, 2004	Aug	CAHN
	AB		10MG	A076118	002	Feb 11, 2004	May	CAHN
>D>	AB		20MG	A076118	003	Feb 11, 2004	Aug	CAHN
	AB		20MG	A076118	003	Feb 11, 2004	May	CAHN
>D>	AB		40MG	A076118	004	Feb 11, 2004	Aug	CAHN
	AB		40MG	A076118	004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
BENZTROPINE MESYLATE

AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

TABLET; ORAL
BENZTROPINE MESYLATE

	@	ACTAVIS TOTOWA	0.5MG	A040699	001	Feb 14, 2008	Jul	DISC
	@		1MG	A040705	001	Feb 14, 2008	Jul	DISC
	@		2MG	A040706	001	Feb 14, 2008	Jul	DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

AB		STI PHARMA LLC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Apr	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

	@	ACTAVIS TOTOWA	5MG	A040552	001	Oct 28, 2004	Jul	DISC
	@		10MG	A040553	001	Oct 28, 2004	Jul	DISC
	@		25MG	A040554	001	Oct 28, 2004	Jul	DISC

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

AB		ROXANE	50MG	A078285	001	Mar 24, 2011	Mar	NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL
PYLERA

	+	AXCAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jun	CAHN

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

	+	SCHERING	200MG	N202258	001	May 13, 2011	May	NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

	@	HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986	Jun	DISC

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	+	B BRAUN	200MG/100ML	N019121	002	Apr 29, 1986	Aug	CTEC
>A>		+		200MG/100ML	N019121	002	Apr 29, 1986	Aug	CTEC
>D>	AP	+		400MG/100ML	N019121	003	Apr 29, 1986	Aug	CTEC
>A>		+		400MG/100ML	N019121	003	Apr 29, 1986	Aug	CTEC
>D>	AP	+	HOSPIRA	200MG/100ML	N019008	002	Apr 29, 1986	Aug	DISC

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>			@ HOSPIRA	200MG/100ML	N019008	002	Apr 29, 1986	Aug	DISC
>D>	AP	+		400MG/100ML	N019008	003	Apr 29, 1986	Aug	DISC
>A>			@	400MG/100ML	N019008	003	Apr 29, 1986	Aug	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

		+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD

BROMFENAC SODIUM

			COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA

XIBROM

			@ ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

	AB		MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA

ENTOCORT EC

	AB	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

			@ AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

			VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
		+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
				522MG	N022108	003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

	AB1		ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA
	AB2			150MG	A091520	001	Jun 09, 2011	May	NEWA
	AB1			150MG	A091459	002	Jun 09, 2011	May	NEWA
	AB1			200MG	A091459	003	Jun 09, 2011	May	NEWA
	AB1		WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN
	AB1			150MG	A079095	002	Mar 24, 2009	May	CAHN
	AB2			150MG	A079094	001	Mar 24, 2009	May	CAHN
	AB1			200MG	A079095	003	Mar 24, 2009	May	CAHN

WELLBUTRIN XL

	AB3	+	VALEANT INTL	150MG	N021515	001	Aug 28, 2003	Jul	CAHN
	AB3			300MG	N021515	002	Aug 28, 2003	Jul	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

>D>	AB		BRISTOL MYERS SQUIBB	5MG	N018731	001	Sep 29, 1986	Aug	DISC
>A>			@	5MG	N018731	001	Sep 29, 1986	Aug	DISC

		TABLET; ORAL							
		BUSPIRONE HYDROCHLORIDE							
		@ ACTAVIS TOTOWA	5MG	A075388	001	May 09, 2002	Jul	DISC	
		@	10MG	A075388	002	May 09, 2002	Jul	DISC	
		@	15MG	A075388	003	May 09, 2002	Jul	DISC	
		@	30MG	A078302	001	Dec 17, 2007	Jul	DISC	
	CALCIPOTRIENE								
		SOLUTION; TOPICAL							
		CALCIPOTRIENE							
	AT	G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA	
	CALCIUM ACETATE								
		SOLUTION; ORAL							
		PHOSLYRA							
		+ FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA	
		TABLET; ORAL							
		CALCIUM ACETATE							
	AB	PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA	
		ELIPHOS							
	AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC	
	CAPTOPRIL								
		TABLET; ORAL							
		CAPTOPRIL							
>A>	AB	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Aug	CAHN	
>A>	AB		25MG	A074477	002	Feb 13, 1996	Aug	CAHN	
>A>	AB		50MG	A074477	003	Feb 13, 1996	Aug	CAHN	
>A>	AB		100MG	A074477	004	Feb 13, 1996	Aug	CAHN	
>D>	AB	PRINSTON PHARM LLC	12.5MG	A074477	001	Feb 13, 1996	Aug	CAHN	
	AB		12.5MG	A074477	001	Feb 13, 1996	May	CAHN	
>D>	AB		25MG	A074477	002	Feb 13, 1996	Aug	CAHN	
	AB		25MG	A074477	002	Feb 13, 1996	May	CAHN	
>D>	AB		50MG	A074477	003	Feb 13, 1996	Aug	CAHN	
	AB		50MG	A074477	003	Feb 13, 1996	May	CAHN	
>D>	AB		100MG	A074477	004	Feb 13, 1996	Aug	CAHN	
	AB		100MG	A074477	004	Feb 13, 1996	May	CAHN	
	CARBAMAZEPINE								
		CAPSULE, EXTENDED RELEASE; ORAL							
		CARBAMAZEPINE							
	AB	NOSTRUM	100MG	A076697	001	May 20, 2011	May	NEWA	
	AB		200MG	A076697	002	May 20, 2011	May	NEWA	
	AB		300MG	A076697	003	May 20, 2011	May	NEWA	
		CARBATROL							
	AB	SHIRE	100MG	N020712	003	Sep 30, 1997	May	CFTG	
	AB		200MG	N020712	001	Sep 30, 1997	May	CFTG	
	AB	+	300MG	N020712	002	Sep 30, 1997	May	CFTG	
		TABLET, CHEWABLE; ORAL							
		CARBAMAZEPINE							
		@ JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN	
	CARBIDOPA; LEVODOPA								
		TABLET; ORAL							
		SINEMET							
	AB	MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN	

TABLET; ORAL
SINEMET

AB		MERCK SHARP DOHME	25MG;100MG	N017555	003		Jan	CAHN
AB	+		25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

AB		MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
AB	+		50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL
CARBINOXAMINE MALEATE

AA		RIVERS EDGE PHARMS	4MG	A090756	001	May 27, 2011	May	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA		MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
AA		PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFACLOR

FOR SUSPENSION; ORAL
CEFACLOR

>D>		@ ACS DOBFAR INFO SA	EQ 125MG BASE/5ML	A062206	001		Aug	CAHN
>D>		@	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988	Aug	CAHN
>D>		@	EQ 250MG BASE/5ML	A062206	002		Aug	CAHN
>D>		@	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988	Aug	CAHN
>A>		@ FACTA FARMA	EQ 125MG BASE/5ML	A062206	001		Aug	CAHN
>A>		@	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988	Aug	CAHN
>A>		@	EQ 250MG BASE/5ML	A062206	002		Aug	CAHN
>A>		@	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL
CEFACLOR

	+	TEVA	EQ 500MG BASE	A065058	002	Sep 04, 2002	Jul	CRLD
		@ WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN
AP		STERI PHARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jul	CMFD
AP			EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

MAXIPIME

>D>	AP	+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N050679	001	Jan 18, 1996	Aug	CAHN
>D>	AP	+		EQ 1GM BASE/VIAL	N050679	002	Jan 18, 1996	Aug	CAHN
>D>	AP	+		EQ 2GM BASE/VIAL	N050679	003	Jan 18, 1996	Aug	CAHN

			INJECTABLE; INJECTION							
			MAXIPIME							
>A>	AP	+	HOSPIRA INC	EQ 500MG BASE/VIAL	N050679	001	Jan 18, 1996	Aug	CAHN
>A>	AP	+		EQ 1GM BASE/VIAL	N050679	002	Jan 18, 1996	Aug	CAHN
>A>	AP	+		EQ 2GM BASE/VIAL	N050679	003	Jan 18, 1996	Aug	CAHN
			CEFOTAXIME SODIUM							
			INJECTABLE; INJECTION							
			CEFOTAXIME SODIUM							
	AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
	AP			EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
	AP			EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
	AP			EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
	AP			EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
	AP			EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN
			CEFOXITIN							
			INJECTABLE; INJECTION							
			CEFOXITIN							
>A>	AP		ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	Aug	NEWA
>A>	AP			EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	Aug	NEWA
>A>	AP			EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	Aug	NEWA
			CEFOXITIN SODIUM							
			INJECTABLE; INJECTION							
			CEFOXITIN							
	AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
	AP			EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
	AP			EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN
			MEFOXIN							
>D>			@ MERCK	EQ 1GM BASE/VIAL	N050517	001		Aug	CAHN
>D>			@	EQ 2GM BASE/VIAL	N050517	002		Aug	CAHN
>D>			@	EQ 10GM BASE/VIAL	N050517	003		Aug	CAHN
>A>			@ MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517	001		Aug	CAHN
>A>			@	EQ 2GM BASE/VIAL	N050517	002		Aug	CAHN
>A>			@	EQ 10GM BASE/VIAL	N050517	003		Aug	CAHN
			CEFPODOXIME PROXETIL							
			TABLET; ORAL							
			CEFPODOXIME PROXETIL							
	AB	+	SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD
			VANTIN							
			@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC
			@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC
			CEFTAZIDIME							
			INJECTABLE; INJECTION							
			CEFTAZIDIME IN DEXTROSE CONTAINER							
			B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jun	NEWA
		+		EQ 2GM BASE	N050823	002	Jun 13, 2011	Jun	NEWA
			CEFTRIAXONE SODIUM							
			INJECTABLE; IM-IV							
			CEFTRIAXONE							
	AP		HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN
	AP			EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN

INJECTABLE; IM-IV
CEFTRIAXONE

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION
CEFTRIAXONE

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	CAHN
AP	+	SANDOZ	EQ 10GM BASE/VIAL	A065168	001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

AB		ALKEM LABS LTD	EQ 250MG BASE	A065496	001	Jun 07, 2010	May	CAHN
AB			EQ 500MG BASE	A065496	002	Jun 07, 2010	May	CAHN
AB		APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Jun	CAHN
AB			EQ 500MG BASE	A065069	002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM

AB		HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC
AP		HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP		HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Jan	CAHN
AP			EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Jan	CAHN
AP			EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

>D>	AB	ACS DOBFAR INFO SA	EQ 250MG BASE	A062118	001		Aug	CAHN
>D>	AB		EQ 500MG BASE	A062118	002		Aug	CAHN
>A>	AB	FACTA FARMA	EQ 250MG BASE	A062118	001		Aug	CAHN
>A>	AB		EQ 500MG BASE	A062118	002		Aug	CAHN

KEFLEX

>A>	AB	SHIONOGI INC	EQ 250MG BASE	N050405	002		Aug	CAHN
>A>		@	EQ 333MG BASE	N050405	004	May 12, 2006	Aug	CAHN
>A>	AB		EQ 500MG BASE	N050405	003		Aug	CAHN
>A>	+		EQ 750MG BASE	N050405	005	May 12, 2006	Aug	CAHN
>D>	AB	VICTORY PHARMA	EQ 250MG BASE	N050405	002		Aug	CAHN
>D>		@	EQ 333MG BASE	N050405	004	May 12, 2006	Aug	CAHN
>D>	AB		EQ 500MG BASE	N050405	003		Aug	CAHN
>D>	+		EQ 750MG BASE	N050405	005	May 12, 2006	Aug	CAHN

FOR SUSPENSION; ORAL
CEPHALEXIN

>D>		@ ACS DOBFAR	EQ 100MG BASE/ML	A062117	001		Aug	CAHN
		@	EQ 100MG BASE/ML	A062117	001		Jan	CAHN
>D>	AB		EQ 125MG BASE/5ML	A062117	002		Aug	CAHN
	AB		EQ 125MG BASE/5ML	A062117	002		Jan	CAHN
>D>	AB	+	EQ 250MG BASE/5ML	A062117	003		Aug	CAHN
	AB	+	EQ 250MG BASE/5ML	A062117	003		Jan	CAHN
>A>		@ FACTA FARMA	EQ 100MG BASE/ML	A062117	001		Aug	CAHN
>A>	AB		EQ 125MG BASE/5ML	A062117	002		Aug	CAHN

		FOR SUSPENSION; ORAL								
		CEPHALEXIN								
>A>	AB	+ FACTA FARMA	EQ 250MG BASE/5ML	A062117	003			Aug	CAHN
		TABLET, FOR SUSPENSION; ORAL								
>D>		PANIXINE DISPERDOSE								
>D>		RANBAXY	EQ 125MG BASE	A065100	002	Sep 11, 2003		Aug	DISC
>D>		+	EQ 250MG BASE	A065100	001	Sep 11, 2003		Aug	DISC
>A>		@ RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003		Aug	DISC
>A>		@	EQ 250MG BASE	A065100	001	Sep 11, 2003		Aug	DISC
		CETIRIZINE HYDROCHLORIDE								
		SYRUP; ORAL								
		CETIRIZINE HYDROCHLORIDE								
>D>	AA	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010		Aug	DISC
>A>		@	5MG/5ML	A078617	001	Feb 02, 2010		Aug	DISC
>D>	AA	PERRIGO ISRAEL	5MG/5ML	A078398	001	Jun 17, 2008		Aug	CAHN
>A>	AA	PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008		Aug	CAHN
		CEVIMELINE HYDROCHLORIDE								
		CAPSULE; ORAL								
>A>		CEVIMELINE								
>A>	AB	APOTEX INC	30MG	A091260	001	Aug 25, 2011		Aug	NEWA
		EVOXAC								
>D>		+ DAIICHI SANKYO CO	30MG	N020989	002	Jan 11, 2000		Aug	CFTG
>A>	AB	+	30MG	N020989	002	Jan 11, 2000		Aug	CFTG
		CHLORHEXIDINE GLUCONATE								
		SOLUTION; DENTAL								
		CHLORHEXIDINE GLUCONATE								
	AT	LYNE	0.12%	A074291	001	Dec 28, 1995		Feb	CAHN
		CHLOROQUINE PHOSPHATE								
		TABLET; ORAL								
		CHLOROQUINE PHOSPHATE								
	AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011		Jan	NEWA
	AA		EQ 300MG BASE	A090612	001	Jan 21, 2011		Jan	NEWA
		CHLOROTHIAZIDE SODIUM								
		INJECTABLE; INJECTION								
		CHLOROTHIAZIDE SODIUM								
	AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011		Jul	NEWA
		CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE								
		SOLUTION; ORAL								
		ZUTRIPRO								
		+ CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439	001	Jun 08, 2011		Jun	NEWA
		CHLORZOXAZONE								
		TABLET; ORAL								
		CHLORZOXAZONE								
		@ ACTAVIS TOTOWA	250MG	A088928	001	May 08, 1987		Jul	DISC
		@	500MG	A040113	001	Sep 29, 1995		Jul	DISC
>D>	AA	OHM LABS	250MG	A081298	001	Dec 29, 1993		Aug	DISC
>A>		@	250MG	A081298	001	Dec 29, 1993		Aug	DISC
>D>	AA		500MG	A081299	001	Dec 29, 1993		Aug	DISC
>A>		@	500MG	A081299	001	Dec 29, 1993		Aug	DISC

CHOLESTYRAMINE

POWDER; ORAL

		CHOLESTYRAMINE						
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD
		CHOLESTYRAMINE LIGHT						
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD
		QUESTRAN						
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC
		QUESTRAN LIGHT						
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

		CICLOPIROX						
AT		TARO	1%	A090269	001	Feb 23, 2011	Feb	NEWA

CILOSTAZOL

TABLET; ORAL

		CILOSTAZOL						
		@ ACTAVIS TOTOWA	100MG	A077028	002	Nov 26, 2004	Jul	DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>		CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>D>	+	HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994	Aug	DISC
>A>		@	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994	Aug	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	TEVA PARENTERAL	200MG/100ML	A077138	001	Mar 18, 2008	Aug	DISC
>D>	AP		400MG/200ML	A077138	002	Mar 18, 2008	Aug	DISC
>A>		@ TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008	Aug	DISC
>A>		@	400MG/200ML	A077138	002	Mar 18, 2008	Aug	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		PROQUIN XR						
		@ DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005	May	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		CIPROFLOXACIN EXTENDED RELEASE						
AB		ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Jun	CMFD
AB			425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION

		PLATINOL						
		@ BRISTOL MYERS	50MG/VIAL	N018057	002		Jun	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB		MYLAN	EQ 10MG BASE	A077042	001	Nov 05, 2004	Apr	CAHN
AB			EQ 20MG BASE	A077042	002	Nov 05, 2004	Apr	CAHN
AB			EQ 40MG BASE	A077042	003	Nov 05, 2004	Apr	CAHN

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

>D>	AA	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993	Aug	DISC
>A>		@	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993	Aug	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HYDROCHLORIDE

AB		MATRIX LABS LTD	EQ 75MG BASE	A091225	001	May 31, 2011	May	NEWA
AB			EQ 150MG BASE	A091225	002	May 31, 2011	May	NEWA
AB			EQ 300MG BASE	A091225	003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLINDAGEL

BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000	Mar	CRLD

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

>D>	AT	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Aug	DISC
>A>		@	EQ 1% BASE	A062811	001	Sep 01, 1988	Aug	DISC
		@ COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL
OLUX

AB	+	STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	May	CAHN

CREAM; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB1	ACTAVIS MID ATLANTIC	0.05%	A074139	001	Aug 03, 1994	Aug	DISC
>A>		@	0.05%	A074139	001	Aug 03, 1994	Aug	DISC
		@ COREPHARMA	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

		@ COREPHARMA	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN

TEMOVATE

>D>	AB1	+ ALTANA	0.05%	N019322	001	Dec 27, 1985	Aug	CAHN
>A>	AB1	+ NYCOMED US	0.05%	N019322	001	Dec 27, 1985	Aug	CAHN

GEL; TOPICAL
TEMOVATE

>D>	AB	+ ALTANA	0.05%	N020337	001	Apr 29, 1994	Aug	CAHN
>A>	AB	+ NYCOMED US	0.05%	N020337	001	Apr 29, 1994	Aug	CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB	ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994	Aug	DISC
>A>		@	0.05%	A074128	001	Aug 03, 1994	Aug	DISC
		@ COREPHARMA	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN

TEMOVATE

>D>	AB	+ ALTANA	0.05%	N019323	001	Dec 27, 1985	Aug	CAHN

OINTMENT; TOPICAL
TEMOVATE

>A>	AB	+	NYCOMED US	0.05%	N019323	001	Dec 27, 1985	Aug	CAHN

SHAMPOO; TOPICAL
CLOBETASOL PROPIONATE

	AB		ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011	May	NEWA

CLOBEX

	AB	+	GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004	May	CFTG

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

>D>	AT		ACTAVIS MID ATLANTIC	0.05%	A074331	001	Dec 15, 1995	Aug	DISC
>A>			@	0.05%	A074331	001	Dec 15, 1995	Aug	DISC
	AT		NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN

TEMOVATE

>D>	AT	+	ALTANA	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN
>A>	AT	+	NYCOMED US	0.05%	N019966	001	Feb 22, 1990	Aug	CAHN

SPRAY; TOPICAL
CLOBETASOL PROPIONATE

	AT		PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May	NEWA

CLOBEX

	AT	+	GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
		+		0.05%	N021835	001	Oct 27, 2005	May	CFTG

CLOCORTOLONE PIVALATE

CREAM; TOPICAL
CLODERM

		+	PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

>A>	AB		MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Aug	CAHN
>A>	AB	+		50MG	N019906	002	Dec 29, 1989	Aug	CAHN
>A>	AB			75MG	N019906	003	Dec 29, 1989	Aug	CAHN
>D>	AB		TYCO HLTHCARE	25MG	N019906	001	Dec 29, 1989	Aug	CAHN
>D>	AB	+		50MG	N019906	002	Dec 29, 1989	Aug	CAHN
>D>	AB			75MG	N019906	003	Dec 29, 1989	Aug	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP		APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA
AP			5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA
AP		HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jul	CAHN
AP			5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jul	CAHN
AP		WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
AP			5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA

CODEINE SULFATE

SOLUTION; ORAL
CODEINE SULFATE

	+	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID AND COLCHICINE

AB		MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN

>A> CRIZOTINIB

>A> CAPSULE; ORAL
>A> XALKORI

>A>		PFIZER	200MG	N202570	001	Aug 26, 2011	Aug	NEWA
>A>	+		250MG	N202570	002	Aug 26, 2011	Aug	NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

>D>	AN	ACTAVIS MID ATLANTIC	10MG/ML	A075067	001	Jul 19, 1999	Aug	DISC
>A>	@		10MG/ML	A075067	001	Jul 19, 1999	Aug	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB		ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
AB	+		30MG	N021777	002	Feb 01, 2007	Apr	CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
AB			30MG	A090738	002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB		JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB			10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB		KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB			10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

>D>	AP	BAXTER HLTHCARE	500MG/VIAL	A040745	001	May 21, 2008	Aug	CRLD
>A>	AP	+	500MG/VIAL	A040745	001	May 21, 2008	Aug	CRLD
>D>	AP		1GM/VIAL	A040745	002	May 21, 2008	Aug	CRLD
>A>	AP	+	1GM/VIAL	A040745	002	May 21, 2008	Aug	CRLD
>D>	AP		2GM/VIAL	A040745	003	May 21, 2008	Aug	CRLD
>A>	AP	+	2GM/VIAL	A040745	003	May 21, 2008	Aug	CRLD

CYTOXAN

>D>	AP	+ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Aug	CRLD
>A>	AP		500MG/VIAL	N012142	003		Aug	CRLD
>D>	AP	+	1GM/VIAL	N012142	004	Aug 30, 1982	Aug	CRLD
>A>	AP		1GM/VIAL	N012142	004	Aug 30, 1982	Aug	CRLD
>D>	AP	+	2GM/VIAL	N012142	005	Aug 30, 1982	Aug	CRLD
>A>	AP		2GM/VIAL	N012142	005	Aug 30, 1982	Aug	CRLD

DANTROLENE SODIUM

CAPSULE; ORAL
DANTROLENE SODIUM

@	ACTAVIS TOTOWA	25MG	A076686	001	Oct 24, 2005	Jul	DISC
@		50MG	A076686	002	Oct 24, 2005	Jul	DISC
@		100MG	A076686	003	Oct 24, 2005	Jul	DISC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
ENABLEX

	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	May	CAHN
+		EQ 15MG BASE	N021513	002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL
PREZISTA

@	TIBOTEC	EQ 300MG BASE	N021976	001	Jun 23, 2006	May	DISC

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

+	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	Jun	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN

	@ COREPHARMA	75MG	N050261	001		May	CAHN
AB		150MG	N050261	002		May	CAHN
AB	+	300MG	N050261	003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB	VERSAPHARM	150MG	A065389	001	Dec 01, 2008	May	CAHN
AB		300MG	A065389	002	Dec 01, 2008	May	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>A>	AB	ACTAVIS TOTOWA	50MG	A071588	001	Jun 05, 1987	Aug	CAHN
>D>	AB	AMIDE PHARM	50MG	A071588	001	Jun 05, 1987	Aug	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR

AB	+ SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

@	CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994	May	DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB		VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB		VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

OINTMENT; TOPICAL

TOPICORT

	+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA		LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
AA		VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA

TABLET; ORAL

DEXAMETHASONE

>D>		@ PAR PHARM	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
>A>	BP		0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
>D>		@	0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
>A>	BP		0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
>D>		@	1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
>A>	BP		1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
>D>		@	4MG	A088238	001	Apr 28, 1983	Aug	CMFD
>A>	BP		4MG	A088238	001	Apr 28, 1983	Aug	CMFD
>D>		@	6MG	A088481	001	Nov 28, 1983	Aug	CMFD
>A>	BP		6MG	A088481	001	Nov 28, 1983	Aug	CMFD
>D>		ROXANE	0.5MG	A084611	001		Aug	CTEC
>A>	BP		0.5MG	A084611	001		Aug	CTEC
>D>			0.75MG	A084613	001		Aug	CTEC
>A>	BP		0.75MG	A084613	001		Aug	CTEC
>D>			1MG	A088306	001	Sep 15, 1983	Aug	CTEC
>A>	BP		1MG	A088306	001	Sep 15, 1983	Aug	CTEC
>D>			2MG	A087916	001	Aug 26, 1982	Aug	CTEC
>A>	BP		2MG	A087916	001	Aug 26, 1982	Aug	CTEC
>D>			4MG	A084612	001		Aug	CTEC
>A>	BP		4MG	A084612	001		Aug	CTEC
>D>		+	6MG	A088316	001	Sep 15, 1983	Aug	CTEC
>A>	BP	+	6MG	A088316	001	Sep 15, 1983	Aug	CTEC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
AP			EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN
>D>	AP	+ TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug	DISC
>A>		@	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
AT		NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

		NOVARTIS	25MG	N021802	008	Apr 21, 2011	May	NEWA
			35MG	N021802	007	Apr 21, 2011	May	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB		COREPHARMA	5MG	N017078	001		Jun	CAHN
AB			10MG	N017078	002		Jun	CAHN
AB	+		15MG	N017078	003		Jun	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634	001		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634	002		Jun	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>		HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986	Aug	DISC
>A>		@	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986	Aug	DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>D>	AB	ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986	Aug	DISC
>A>		@	2MG	A070781	001	Mar 19, 1986	Aug	DISC
>D>	AB		5MG	A070706	001	Mar 19, 1986	Aug	DISC
>A>		@	5MG	A070706	001	Mar 19, 1986	Aug	DISC
>D>	AB		10MG	A070707	001	Mar 19, 1986	Aug	DISC
>A>		@	10MG	A070707	001	Mar 19, 1986	Aug	DISC

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB		VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA		LANNETT HOLDINGS INC	25MG	A200177	001	Jul 18, 2011	Jul	NEWA

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008	May	CAHN

DIGOXIN

TABLET; ORAL

DIGOXIN

		@ ACTAVIS TOTOWA	0.125MG	A040282	001	Dec 23, 1999	Jul	DISC
		@	0.25MG	A040282	002	Dec 23, 1999	Jul	DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3		VALEANT INTL	120MG	N020062	001	Aug 10, 1992	Jun	CAHN
AB3			180MG	N020062	002	Dec 27, 1991	Jun	CAHN
AB3			240MG	N020062	003	Dec 27, 1991	Jun	CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Jun	CAHN
BC	+		360MG	N020062	005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

AB3		VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Apr	CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Apr	CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Apr	CAHN

TIAZAC

AB4		VALEANT INTL	120MG	N020401	001	Sep 11, 1995	Jun	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Jun	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Jun	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Jun	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Jun	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Jun	CAHN

TABLET; ORAL

CARDIZEM

AB		VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
AB			60MG	N018602	002	Nov 05, 1982	Jun	CAHN
AB			90MG	N018602	003	Dec 08, 1986	Jun	CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

>D> AB		MYLAN	30MG	A073185	001	Nov 05, 1992	Aug	CMS2
>A> AB			30MG	A072838	004	Nov 05, 1992	Aug	CMS1
>A>		@	30MG	A073185	001	Nov 05, 1992	Aug	CMS2
>D> AB			60MG	A073186	001	Nov 05, 1992	Aug	CMS2
>A> AB			60MG	A072838	003	Nov 05, 1992	Aug	CMS1
>A>		@	60MG	A073186	001	Nov 05, 1992	Aug	CMS2
>D> AB			90MG	A072837	001	Nov 05, 1992	Aug	CMS2

		TABLET; ORAL							
		DILTIAZEM HYDROCHLORIDE							
>A>		@ MYLAN	90MG	A072837	001	Nov 05, 1992	Aug		CMS2
>A>	AB		90MG	A072838	002	Nov 05, 1992	Aug		CMS1
		TABLET, EXTENDED RELEASE; ORAL							
		CARDIZEM LA							
	AB	VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun		CAHN
	AB		180MG	N021392	002	Feb 06, 2003	Jun		CAHN
	AB		240MG	N021392	003	Feb 06, 2003	Jun		CAHN
	AB		300MG	N021392	004	Feb 06, 2003	Jun		CAHN
	AB		360MG	N021392	005	Feb 06, 2003	Jun		CAHN
	AB	+	420MG	N021392	006	Feb 06, 2003	Jun		CAHN
		DIPYRIDAMOLE							
		INJECTABLE; INJECTION							
>D>		DIPYRIDAMOLE							
>D>	AP	HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997	Aug		DISC
>A>		@	5MG/ML	A074601	001	Dec 19, 1997	Aug		DISC
		TABLET; ORAL							
		DIPYRIDAMOLE							
	AB	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb		CAHN
	AB		50MG	A040542	002	Apr 21, 2006	Feb		CAHN
	AB		75MG	A040542	003	Apr 21, 2006	Feb		CAHN
		DISULFIRAM							
		TABLET; ORAL							
		ANTABUSE							
	AB	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar		CTEC
	AB	+	500MG	A088483	001	Dec 08, 1983	Mar		CTEC
		DISULFIRAM							
	AB	SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar		NEWA
	AB		500MG	A091619	002	Mar 28, 2011	Mar		NEWA
		DIVALPROEX SODIUM							
		CAPSULE, DELAYED REL PELLETS; ORAL							
		DIVALPROEX SODIUM							
	AB	MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar		NEWA
		TABLET, DELAYED RELEASE; ORAL							
		DIVALPROEX SODIUM							
	AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr		NEWA
	AB		EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr		NEWA
	AB		EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr		NEWA
	AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar		NEWA
	AB		EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar		NEWA
	AB		EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar		NEWA
	AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb		NEWA
		DOBUTAMINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		DOBUTAMINE HYDROCHLORIDE							
>D>	AP	HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Aug		CRLD
>A>	AP	+	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Aug		CRLD
>D>	AP	TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993	Aug		DISC
>A>		@	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993	Aug		DISC

DOCETAXEL

INJECTABLE; INJECTION

		DOCEFREZ							
	+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	May	NEWA
	+		80MG/VIAL	N022534	002	May 03, 2011	May	NEWA
		DOCETAXEL							
		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun	NEWA
			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun	NEWA
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA
AP		SANDOZ	20MG/2ML (10MG/ML)	N201525	001	Jun 29, 2011	Jun	NEWA
AP			80MG/8ML(10MG/ML)	N201525	002	Jun 29, 2011	Jun	NEWA
AP			160MG/16ML (10MG/ML)	N201525	003	Jun 29, 2011	Jun	NEWA
		TAXOTERE							
		@ SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

		DONEPEZIL HYDROCHLORIDE							
>A>	AB	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Aug	NEWA
>A>	AB		10MG	A201335	002	Aug 29, 2011	Aug	NEWA
	AB	ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	May	NEWA
	AB		10MG	A090551	002	May 31, 2011	May	NEWA
	AB	APOTEX	5MG	A078841	001	Jun 02, 2011	May	NEWA
	AB		10MG	A078841	002	Jun 02, 2011	May	NEWA
	AB	AUROBINDO	5MG	A090056	001	May 31, 2011	May	NEWA
	AB		10MG	A090056	002	May 31, 2011	May	NEWA
	AB	CIPLA LTD	5MG	A077518	001	May 31, 2011	May	NEWA
	AB		10MG	A077518	002	May 31, 2011	May	NEWA
	AB	DR REDDYS LABS LTD	5MG	A201001	001	May 31, 2011	May	NEWA
	AB		10MG	A201001	002	May 31, 2011	May	NEWA
	AB	HIKMA PHARMS	5MG	A090247	001	May 31, 2011	May	NEWA
	AB		10MG	A090247	002	May 31, 2011	May	NEWA
	AB	HUAHAI US INC	5MG	A200292	001	May 31, 2011	May	NEWA
	AB		10MG	A200292	002	May 31, 2011	May	NEWA
	AB	JUBILANT LIFE	5MG	A090768	001	May 31, 2011	May	NEWA
	AB		10MG	A090768	002	May 31, 2011	May	NEWA
	AB	MATRIX LABS LTD	5MG	A090521	001	May 31, 2011	May	NEWA
	AB		10MG	A090521	002	May 31, 2011	May	NEWA
	AB	PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	May	NEWA
	AB		10MG	A090425	002	May 31, 2011	May	NEWA
	AB	ROXANE	5MG	A078662	001	May 31, 2011	May	NEWA
	AB		10MG	A078662	002	May 31, 2011	May	NEWA
	AB	SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
	AB		10MG	A090290	002	May 31, 2011	May	NEWA
	AB	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
	AB		10MG	A090493	002	May 31, 2011	May	NEWA
	AB	TEVA	5MG	A077344	001	May 31, 2011	May	NEWA
	AB		10MG	A077344	002	May 31, 2011	May	NEWA
	AB	TORRENT PHARMS	5MG	A090686	001	May 31, 2011	May	NEWA
	AB		10MG	A090686	002	May 31, 2011	May	NEWA

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB		WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
AB			10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

AB		SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB			10MG	A091198	002	May 10, 2011	Apr	NEWA
AB		ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB			10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

>D>	AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
>A>		@	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
>A>		@	EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
>A>		@	EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
>D>	AB		EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC
>A>		@	EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB		MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB		WATSON LABS FLORIDA	EQ 50MG BASE	A062031	002	Oct 13, 1982	May	CAHN
AB			EQ 100MG BASE	A062031	001		May	CAHN

DRONABINOL

CAPSULE; ORAL
DRONABINOL

>A>	AB	INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011	Aug	NEWA
>A>	AB		5MG	A078501	002	Aug 19, 2011	Aug	NEWA
>A>	AB		10MG	A078501	003	Aug 19, 2011	Aug	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
LORYNA

AB		SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA

TABLET; ORAL-28
SYEDA

AB		SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

		@ ORTHO JANSSEN	1%	N018751	001	Dec 23, 1982	Jul	CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

>D>	AP		HOSPIRA	10MG/ML	A040131	001	Feb 24, 1998	Aug	DISC
>A>		@		10MG/ML	A040131	001	Feb 24, 1998	Aug	DISC

>A> EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET; ORAL
>A> COMPLERA

>A>		+	GILEAD SCIENCES INC	200MG;25MG;300MG	N202123	001	Aug 10, 2011	Aug	NEWA

ENALAPRIL MALEATE

TABLET; ORAL
VASOTEC

	AB		VALEANT INTL	2.5MG	N018998	005	Jul 26, 1988	Jun	CAHN
	AB			5MG	N018998	001	Dec 24, 1985	Jun	CAHN
	AB			10MG	N018998	002	Dec 24, 1985	Jun	CAHN
	AB	+		20MG	N018998	003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

	AB		VALEANT INTL	5MG;12.5MG	N019221	003	Jul 12, 1995	Jun	CAHN
	AB	+		10MG;25MG	N019221	001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
LOVENOX

			SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
ELESTAT

	AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG

EPINASTINE HYDROCHLORIDE

	AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST FORTE DENTAL

>D>		+	DENTSPLY PHARM	0.005MG/ML;4%	N021383	001		Aug	CFTG
>A>	AP	+		0.005MG/ML;4%	N021383	001		Aug	CFTG

>A> PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

>A>	AP		SEPTODONT INC	0.005MG/ML;4%	A078959	001	Aug 30, 2011	Aug	NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

	AP		MUSTAFA NEVSAT	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Apr	NEWA
	AP			50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Apr	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
EPOPROSTENOL SODIUM

>D>		+	ACTELION	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Aug	CTNA

		INJECTABLE; INJECTION							
>A>		VELETRI							
>A>	+	ACTELION	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Aug	CTNA	
		ERYTHROMYCIN							
		CAPSULE, DELAYED REL PELLETS; ORAL							
		ERYTHROMYCIN							
AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN	
		GEL; TOPICAL							
		E-GLADES							
AT		COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr	CAHN	
		OINTMENT; OPHTHALMIC							
		ERYTHROMYCIN							
AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN	
AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN	
		SOLUTION; TOPICAL							
		ERYDERM							
		@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN	
		ERYTHROMYCIN							
		@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr	CAHN	
		SWAB; TOPICAL							
		ERYCETTE							
		@ ORTHO JANSSEN	2%	N050594	001	Feb 15, 1985	Jul	CAHN	
		ERYTHROMYCIN							
		@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr	CAHN	
		TABLET; ORAL							
		ERYTHROMYCIN							
		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN	
	+		500MG	A061621	002		Jan	CAHN	
		TABLET, COATED PARTICLES; ORAL							
		PCE							
		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN	
	+		500MG	N050611	002	Aug 22, 1990	Jan	CAHN	
		TABLET, DELAYED RELEASE; ORAL							
		E-MYCIN							
		@ ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN	
		@	333MG	A060272	002		Jan	CAHN	
		ERY-TAB							
	+	ARBOR PHARMS INC	250MG	A062298	001		Jan	CAHN	
	+		333MG	A062298	003	Mar 29, 1982	Jan	CAHN	
	+		500MG	A062298	002		Jan	CAHN	
		ERYTHROMYCIN ETHYLSUCCINATE							
		GRANULE; ORAL							
		E.E.S.							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan	CAHN	
		ERYPED							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan	CAHN	
	+		EQ 400MG BASE/5ML	N050207	002		Jan	CAHN	
		SUSPENSION; ORAL							
		E.E.S. 200							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan	CAHN	
		E.E.S. 400							
AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan	CAHN	
		PEDIAMYCIN							
AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan	CAHN	

		SUSPENSION; ORAL							
		PEDIAMYCIN 400							
	AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002			Jan	CAHN
		TABLET; ORAL							
		E.E.S. 400							
		@ ARBOR PHARMS INC	EQ 400MG BASE	A061905	001			Jan	CAHN
	BX	+	EQ 400MG BASE	A061905	002	Aug 12, 1982		Jan	CAHN
		ERYTHROMYCIN ETHYLSUCCINATE							
	BX	+ ARBOR PHARMS INC	EQ 400MG BASE	A061904	001			Jan	CAHN
		TABLET, CHEWABLE; ORAL							
		E.E.S.							
		@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	002			Jan	CAHN
		ERYPED							
		@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	003	Jul 05, 1988		Jan	CAHN
		ERYTHROMYCIN STEARATE							
		TABLET; ORAL							
		ERYTHROCIN STEARATE							
		@ ARBOR PHARMS INC	EQ 125MG BASE	A060359	002			Jan	CAHN
>D>			EQ 250MG BASE	A060359	001			Aug	CRLD
>A>		+	EQ 250MG BASE	A060359	001			Aug	CRLD
			EQ 250MG BASE	A060359	001			Jan	CAHN
>D>		+	EQ 500MG BASE	A060359	003			Aug	DISC
>A>		@	EQ 500MG BASE	A060359	003			Aug	DISC
		+	EQ 500MG BASE	A060359	003			Jan	CAHN
		ESTRADIOL							
		TABLET; ORAL							
		ESTRACE							
>D>	AB	BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993		Aug	DISC
>A>		@	0.5MG	A081295	001	Jun 30, 1993		Aug	DISC
		ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL							
		ACTIVELLA							
	AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006		Mar	CTEC
		ESTRADIOL AND NORETHINDRONE ACETATE							
	AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324	002	Jun 09, 2011		May	NEWA
		ESTROPIPATE							
		CREAM; VAGINAL							
		OGEN							
		@ PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001			Apr	DISC
		ESZOPICLONE							
		TABLET; ORAL							
		ESZOPICLONE							
>A>	AB	LUPIN LTD	1MG	A091124	001	Sep 13, 2011		Aug	NEWA
>A>	AB		2MG	A091124	002	Sep 13, 2011		Aug	NEWA
>A>	AB		3MG	A091124	003	Sep 13, 2011		Aug	NEWA
		@ TEVA	1MG	A091169	001	May 23, 2011		Jun	DISC
	AB		1MG	A091169	001	May 23, 2011		May	NEWA
		@	2MG	A091169	002	May 23, 2011		Jun	DISC
	AB		2MG	A091169	002	May 23, 2011		May	NEWA
		@	3MG	A091169	003	May 23, 2011		Jun	DISC
	AB		3MG	A091169	003	May 23, 2011		May	NEWA

		TABLET; ORAL							
		ESZOPICLONE							
		@ WOCKHARDT LTD	1MG	A091165	001	Jul 14, 2011	Jul		NEWA
		@	2MG	A091165	002	Jul 14, 2011	Jul		NEWA
		@	3MG	A091165	003	Jul 14, 2011	Jul		NEWA
		LUNESTA							
>D>		SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Aug		CTEC
>A>	AB		1MG	N021476	001	Dec 15, 2004	Aug		CTEC
			1MG	N021476	001	Dec 15, 2004	Jun		CTEC
	AB		1MG	N021476	001	Dec 15, 2004	May		CFTG
>D>			2MG	N021476	002	Dec 15, 2004	Aug		CTEC
>A>	AB		2MG	N021476	002	Dec 15, 2004	Aug		CTEC
			2MG	N021476	002	Dec 15, 2004	Jun		CTEC
	AB		2MG	N021476	002	Dec 15, 2004	May		CFTG
>D>		+	3MG	N021476	003	Dec 15, 2004	Aug		CTEC
>A>	AB	+	3MG	N021476	003	Dec 15, 2004	Aug		CTEC
		+	3MG	N021476	003	Dec 15, 2004	Jun		CTEC
	AB	+	3MG	N021476	003	Dec 15, 2004	May		CFTG
		ETHINYL ESTRADIOL; LEVONORGESTREL							
		TABLET; ORAL							
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May		NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	May		NEWA
		LOSEASONIQUE							
>D>		DURAMED	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Aug		CAHN
>A>		TEVA WOMENS	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Aug		CAHN
		LYBREL							
	AB	+ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May		CFTG
		SEASONIQUE							
	AB	+ TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	May		CFTG
		TABLET; ORAL-21							
		ALESSE							
>D>		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Aug		CAHN
		@	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Jul		CAHN
>A>		@ WYETH PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Aug		CAHN
		TRIPHASIL-21							
>D>		@ AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N019192	001	Nov 01, 1984	Aug		CAHN
>A>		@ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N019192	001	Nov 01, 1984	Aug		CAHN
		TABLET; ORAL-28							
		ALESSE							
>D>		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Aug		CAHN
		@	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Jul		CAHN
>A>		@ WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Aug		CAHN
		ORSYTHIA							
	AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr		NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET; ORAL-28							
		BRIELLYN							
	AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar		NEWA
		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
		+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan		CRLD

		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN	
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL							
		LO LOESTRIN FE							
	+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD	
		TABLET; ORAL-28							
		GILDESS FE 1.5/30							
	AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA	
		GILDESS FE 1/20							
	AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA	
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET; ORAL							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
	AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA	
		TABLET; ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA	
		ETHINYL ESTRADIOL; NORGESTREL							
		TABLET; ORAL-21							
		OVRAL							
>D>		@ AKRIMAX PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN	
>A>		@ WYETH PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN	
		TABLET; ORAL-28							
		LO/OVRAL-28							
>D>	AB	AKRIMAX PHARMS	0.03MG;0.3MG	N017802	001		Aug	CAHN	
>A>	AB	WYETH PHARMS	0.03MG;0.3MG	N017802	001		Aug	CAHN	
		OVRAL-28							
>A>		@ WYETH PHARMS	0.05MG;0.5MG	N016806	001		Aug	CAHN	
>D>		@ WYETH PHARMS INC	0.05MG;0.5MG	N016806	001		Aug	CAHN	
		ETHOSUXIMIDE							
		CAPSULE; ORAL							
		ETHOSUXIMIDE							
	AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN	
		ETODOLAC							
		CAPSULE; ORAL							
		ETODOLAC							
		@ MYLAN	200MG	A075071	001	Sep 30, 1998	Feb	CAHN	
		@	300MG	A075071	002	Sep 30, 1998	Feb	CAHN	
		TABLET; ORAL							
		ETODOLAC							
>D>	AB	ACTAVIS ELIZABETH	400MG	A074819	001	Feb 28, 1997	Aug	DISC	
>A>		@	400MG	A074819	001	Feb 28, 1997	Aug	DISC	
		@ MYLAN	400MG	A075012	001	Sep 30, 1998	Feb	CAHN	
		@	500MG	A075012	002	Sep 30, 1998	Feb	CAHN	

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011	May	NEWA

ETRAVIRINE

TABLET; ORAL

INTELENCE

	TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD
+		200MG	N022187	002	Dec 22, 2010	Jan	NEWA

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+ PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG

EXEMESTANE

AB	ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA

EZOGABINE

TABLET; ORAL

POTIGA

	VALEANT PHARMS	50MG	N022345	001	Jun 10, 2011	Jun	NEWA
		200MG	N022345	002	Jun 10, 2011	Jun	NEWA
		300MG	N022345	003	Jun 10, 2011	Jun	NEWA
+		400MG	N022345	004	Jun 10, 2011	Jun	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	APOTEX	125MG	A091480	001	Jul 22, 2011	Jul	NEWA
AB		250MG	A091480	002	Jul 22, 2011	Jul	NEWA
AB		500MG	A091480	003	Jul 22, 2011	Jul	NEWA
AB	AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A091114	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A091114	003	Mar 21, 2011	Mar	NEWA
AB	MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
AB		250MG	A201333	002	Mar 24, 2011	Mar	NEWA
AB		500MG	A201333	003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A090128	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128	003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D> AP	HOSPIRA	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
>A>	@	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN

PEPCID

	@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC

		INJECTABLE; INJECTION							
		PEPCID PRESERVATIVE FREE							
		@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan		DISC
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER							
		@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan		DISC
		TABLET; ORAL							
		FAMOTIDINE							
>D>	AB	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001	Aug		DISC
>A>		@	20MG	A075650	001	Sep 14, 2001	Aug		DISC
>D>	AB		40MG	A075650	002	Sep 14, 2001	Aug		DISC
>A>		@	40MG	A075650	002	Sep 14, 2001	Aug		DISC
	AB	ALEMBIC PHARMS LTD	20MG	A078916	001	May 22, 2009	Jul		CAHN
	AB		40MG	A078916	002	May 22, 2009	Jul		CAHN
	AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb		CAHN
	AB		40MG	A075457	002	Apr 18, 2001	Feb		CAHN
		FAMOTIDINE; IBUPROFEN							
		TABLET; ORAL							
		DUEXIS							
		+ HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr		NEWA
		FELBAMATE							
		TABLET; ORAL							
>A>		FELBAMATE							
>A>	AB	AMNEAL PHARMS	400MG	A201680	001	Sep 13, 2011	Aug		NEWA
>A>	AB		600MG	A201680	002	Sep 13, 2011	Aug		NEWA
		FELBATOL							
>D>		MEDA PHARMS	400MG	N020189	001	Jul 29, 1993	Aug		CFTG
>A>	AB		400MG	N020189	001	Jul 29, 1993	Aug		CFTG
>D>		+	600MG	N020189	002	Jul 29, 1993	Aug		CFTG
>A>	AB	+	600MG	N020189	002	Jul 29, 1993	Aug		CFTG
		FENOFIBRATE							
		TABLET; ORAL							
		FENOGLIDE							
		SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb		CAHN
		+	120MG	N022118	002	Aug 10, 2007	Feb		CAHN
		FENTANYL							
		FILM, EXTENDED RELEASE; TRANSDERMAL							
		FENTANYL-100							
	AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan		NEWA
		FENTANYL-25							
	AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan		NEWA
		FENTANYL-50							
	AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan		NEWA
		FENTANYL-75							
	AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan		NEWA
		FENTANYL CITRATE							
		SPRAY, METERED; NASAL							
		LAZANDA							
		ARCHIMEDES	100MCG	N022569	001	Jun 30, 2011	Jun		NEWA
		+	400MCG	N022569	002	Jun 30, 2011	Jun		NEWA

		TABLET; SUBLINGUAL							
		ABSTRAL							
		PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA	
			EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA	
			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA	
	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA	
			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA	
			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Jan	NEWA	
		FIDAXOMICIN							
		TABLET; ORAL							
		DIFICID							
	+	OPTIMER PHARMS	200MG	N201699	001	May 27, 2011	May	NEWA	
		FINASTERIDE							
		TABLET; ORAL							
		FINASTERIDE							
>A>	AB	SUN PHARMA GLOBAL	5MG	A090507	001	Aug 16, 2011	Aug	NEWA	
		FLUCONAZOLE							
		TABLET; ORAL							
		FLUCONAZOLE							
	AB	AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Feb	NEWA	
	AB		100MG	A078423	002	Mar 07, 2011	Feb	NEWA	
	AB		150MG	A078423	003	Mar 07, 2011	Feb	NEWA	
	AB		200MG	A078423	004	Mar 07, 2011	Feb	NEWA	
	AB	MYLAN	50MG	A076042	001	Jul 29, 2004	Feb	CAHN	
	AB		100MG	A076042	002	Jul 29, 2004	Feb	CAHN	
	AB		150MG	A076042	003	Jul 29, 2004	Feb	CAHN	
	AB		200MG	A076042	004	Jul 29, 2004	Feb	CAHN	
		FLUCYTOSINE							
		CAPSULE; ORAL							
		ANCOBON							
	AB	VALEANT	250MG	N017001	001		Jun	CFTG	
	AB	+	500MG	N017001	002		Jun	CFTG	
		FLUCYTOSINE							
	AB	SIGMAPHARM LABS LLC	250MG	A201566	001	Jun 28, 2011	Jun	NEWA	
	AB		500MG	A201566	002	Jun 28, 2011	Jun	NEWA	
		FLUDARABINE PHOSPHATE							
		TABLET; ORAL							
		OFORTA							
	+	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	Apr	CMFD	
		@	10MG	N022273	001	Dec 18, 2008	Jan	DISC	
		FLUDEOXYGLUCOSE F-18							
		INJECTABLE; INTRAVENOUS							
		FLUDEOXYGLUCOSE F18							
	AP	+ FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC	
	AP	PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA	
		FLUDROCORTISONE ACETATE							
		TABLET; ORAL							
		FLUDROCORTISONE ACETATE							
	AB	WEST-WARD PHARM CORP	0.1MG	A091302	001	Jul 22, 2011	Jul	NEWA	

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		PFIZER	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	May	CAHN
AP			1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	May	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787	004		Jun	CAHN
AT	+		0.025%	N012787	005		Jun	CAHN
AT	+		0.025%	N012787	002		Jun	CAHN

SYNALAR-HP

		@ MEDIMETRIKS PHARMS	0.2%	N016161	002		Jun	CAHN

OINTMENT; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.025%	N013960	001		Jun	CAHN

SOLUTION; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N015296	001		Jun	CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

>D>		@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Aug	CAHN
>A>		@ MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Aug	CAHN

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP		SANDOZ	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Apr	NEWA
AP			2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Apr	NEWA
		@ VALEANT	500MG/10ML (50MG/ML)	N012209	001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009	Apr	CAHN
AB1			EQ 20MG BASE	A090223	002	Mar 19, 2009	Apr	CAHN
AB			EQ 40MG BASE	A090223	003	Mar 19, 2009	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

		@ WATSON PHARMS	0.025%	N012806	003		Jul	DISC
		@	0.05%	N012806	002		Jul	DISC

OINTMENT; TOPICAL

CORDRAN

		@ WATSON PHARMS	0.025%	N012806	004		Jun	DISC
		@	0.05%	N012806	001		Jun	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB		MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUTICASONE PROPIONATE

LOTION; TOPICAL

		CUTIVATE						
AB	+	NYCOMED US	0.05%	N021152	001	Mar 31, 2005	Apr	CFTG
		FLUTICASONE PROPIONATE						
AB		GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Apr	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

		FLUVOXAMINE MALEATE						
		@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
		@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL

		FOLIC ACID						
AA	+	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
AA		JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

		ARIXTRA						
AP	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG
		FONDAPARINUX SODIUM						
AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jun	NEWA
AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jun	NEWA
AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jun	NEWA
AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jun	NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION

		FORADIL CERTIHALER						
		@ NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC

FOSINOPRIL SODIUM

TABLET; ORAL

		FOSINOPRIL SODIUM						
AB		AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
AB			20MG	A091163	002	Mar 30, 2011	Mar	NEWA
AB			40MG	A091163	003	Mar 30, 2011	Mar	NEWA

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB		EMCURE PHARMS USA	10MG;12.5MG	A079025	001	Sep 17, 2010	Jul	CAHN
AB			20MG;12.5MG	A079025	002	Sep 17, 2010	Jul	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

		FOSPHENYTOIN SODIUM						
AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
AP		PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		MARKSANS PHARMA	100MG	A090007	001	Jul 21, 2011	Jul	NEWA
AB			300MG	A090007	002	Jul 21, 2011	Jul	NEWA
AB			400MG	A090007	003	Jul 21, 2011	Jul	NEWA
AB		MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
AB			300MG	A090158	002	Feb 14, 2011	Jan	NEWA
AB			400MG	A090158	003	Feb 14, 2011	Jan	NEWA
AB		MYLAN	100MG	A090158	001	Feb 14, 2011	May	CAHN
AB			300MG	A090158	002	Feb 14, 2011	May	CAHN
AB			400MG	A090158	003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA		HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

AB		HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jul	NEWA
AB			800MG	A078782	002	Jul 21, 2011	Jul	NEWA
AB		ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
AB			800MG	A078926	002	Feb 11, 2011	Jan	NEWA

GRALISE

BX	+	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544	002	Jan 28, 2011	Jan	NEWA
BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011	Jul	CAHN
BX	+		600MG	N022544	002	Jan 28, 2011	Jul	CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	+	GLAXO GRP LTD	600MG	N022399	001	Apr 06, 2011	Apr	NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

	+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
	+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
	+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
	+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
	+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

RAZADYNE ER

AB	+	JANSSEN PHARMS	EQ 8MG BASE	N021615	001	Apr 01, 2005	Jul	CAHN
AB			EQ 16MG BASE	N021615	002	Apr 01, 2005	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

RAZADYNE ER

	AB		JANSSEN PHARMS	EQ 24MG BASE	N021615	003	Apr 01, 2005	Jul CAHN

SOLUTION; ORAL

RAZADYNE

	AA	+	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	Jul CAHN

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB		ACTAVIS ELIZABETH	EQ 4MG BASE	A077585	001	Sep 15, 2009	Aug DISC
>A>		@		EQ 4MG BASE	A077585	001	Sep 15, 2009	Aug DISC
>D>	AB			EQ 8MG BASE	A077585	002	Sep 15, 2009	Aug DISC
>A>		@		EQ 8MG BASE	A077585	002	Sep 15, 2009	Aug DISC
>D>	AB			EQ 12MG BASE	A077585	003	Sep 15, 2009	Aug DISC
>A>		@		EQ 12MG BASE	A077585	003	Sep 15, 2009	Aug DISC
	AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar NEWA
	AB			EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar NEWA
	AB			EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar NEWA
	AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan NEWA
	AB			EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan NEWA
	AB			EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan NEWA

RAZADYNE

	AB	+	JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	Jul CAHN
	AB			EQ 8MG BASE	N021169	002	Feb 28, 2001	Jul CAHN
	AB			EQ 12MG BASE	N021169	003	Feb 28, 2001	Jul CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

>A>								
>A>	AT		APOTEX CORP	0.3%	A079084	001	Aug 19, 2011	Aug NEWA

ZYMAR

>D>		+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Aug CFTG
>A>	AT	+		0.3%	N021493	001	Mar 28, 2003	Aug CFTG

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

>A>								
>A>		+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Aug NEWA
>A>		+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Aug NEWA
>A>		+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Aug NEWA
		+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb CRLD

GEMCITABINE HYDROCHLORIDE

	AP		ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Jul NEWA
	AP			EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Jul NEWA
	AP			EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Jul NEWA
	AP		ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Jul NEWA
	AP			EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Jul NEWA
	AP		APP PHARMS	EQ 2GM BASE/VIAL	A090242	003	May 16, 2011	May NEWA
	AP		DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365	001	Jul 25, 2011	Jul NEWA
	AP			EQ 1GM BASE/VIAL	A091365	002	Jul 25, 2011	Jul NEWA
	AP		FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jul NEWA
	AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jul NEWA
	AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	May NEWA
	AP		HOSPIRA	EQ 200MG BASE/VIAL	A078339	001	Jul 25, 2011	Jul NEWA
	AP			EQ 1GM BASE/VIAL	A078339	002	Jul 25, 2011	Jul NEWA
	AP	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Jul CTEC
		+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	May CTNA

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Jul	NEWA
AP		SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078433	002	Jul 25, 2011	Jul	NEWA
AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA
AP		WATSON LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB			4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>D>	AB	ALPHAPHARM	5MG	A074438	001	Jun 20, 1995	Aug	CAHN
>D>	AB		10MG	A074438	002	Jun 20, 1995	Aug	CAHN
>A>	AB	MYLAN	5MG	A074438	001	Jun 20, 1995	Aug	CAHN
>A>	AB		10MG	A074438	002	Jun 20, 1995	Aug	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	TEVA PHARMS	5MG;500MG	A077270	003	Oct 28, 2005	Aug	CRLD
>A>	AB	+	5MG;500MG	A077270	003	Oct 28, 2005	Aug	CRLD
	AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
	AB		2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
	AB		5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA
>D>		METAGLIP						
>D>	AB	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Aug	DISC
>A>		@	2.5MG;250MG	N021460	001	Oct 21, 2002	Aug	DISC
>D>	AB		2.5MG;500MG	N021460	002	Oct 21, 2002	Aug	DISC

TABLET; ORAL
>D> METAGLIP
>A> @ BRISTOL MYERS SQUIBB 2.5MG;500MG N021460 002 Oct 21, 2002 Aug DISC
>D> AB + 5MG;500MG N021460 003 Oct 21, 2002 Aug DISC
>A> @ 5MG;500MG N021460 003 Oct 21, 2002 Aug DISC

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE
+ EMMAUS MEDCL 5GM/PACKET N021667 001 Jun 10, 2004 May CAHN

GLYBURIDE

TABLET; ORAL
GLYBURIDE
@ ACTAVIS TOTOWA 1.5MG A075947 001 Nov 14, 2002 Jul DISC
@ 3MG A075947 002 Nov 14, 2002 Jul DISC
@ 6MG A075947 003 Nov 14, 2002 Jul DISC
AB HERITAGE PHARMS INC 1.25MG A090937 001 Feb 28, 2011 May CAHN
AB 2.5MG A090937 002 Feb 28, 2011 May CAHN
AB 5MG A090937 003 Feb 28, 2011 May CAHN
AB INDICUS PHARMA 1.25MG A090937 001 Feb 28, 2011 Feb NEWA
AB 2.5MG A090937 002 Feb 28, 2011 Feb NEWA
AB 5MG A090937 003 Feb 28, 2011 Feb NEWA

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL
SANCUSO
+ PROSTRAKAN INC 3.1MG/24HR N022198 001 Sep 12, 2008 Jun CAHN

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
FULVICIN P/G
@ ELORAC 125MG A061996 001 Jan CAHN
@ 250MG A061996 002 Jan CAHN
FULVICIN P/G 165
@ ELORAC 165MG A061996 003 Apr 06, 1982 Jan CAHN
FULVICIN P/G 330
@ ELORAC 330MG A061996 004 Apr 06, 1982 Jan CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE
>D> AB ACTAVIS MID ATLANTIC 0.05% A077109 001 Jun 14, 2005 Aug DISC
>A> @ 0.05% A077109 001 Jun 14, 2005 Aug DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL
AP PFIZER EQ 5MG BASE/ML A078347 001 Sep 14, 2009 May CAHN
>A> AP SAGENT PHARMS EQ 5MG BASE/ML A091637 001 Sep 02, 2011 Aug NEWA
>A> AP EQ 5MG BASE/ML A200742 001 Sep 02, 2011 Aug NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM
PFIZER 1,000 UNITS/ML N201370 001 Jul 21, 2011 Jul NEWA

	INJECTABLE; INJECTION							
	HEPARIN SODIUM							
	PFIZER	5,000 UNITS/ML	N201370	002	Jul 21, 2011	Jul	NEWA	
		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jul	NEWA	
AP	SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011	May	NEWA	
AP		5,000 UNITS/ML	A091659	001	Jun 08, 2011	May	NEWA	
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	May	NEWA	
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	May	NEWA	
	HEPARIN SODIUM PRESERVATIVE FREE							
	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Jul	NEWA	
	HEXAMINOLEVULINATE HYDROCHLORIDE							
	FOR SOLUTION; INTRAVESICAL							
	CYSVIEW KIT							
+	GE HEALTHCARE	100MG/VIAL	N022555	001	May 28, 2010	May	CAHN	
	HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE							
	TABLET; ORAL							
	HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE							
AB	NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Apr	NEWA	
	TUSSIGON							
AB +	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC	
	HYALURONIDASE							
	INJECTABLE; INJECTION							
	HYDASE							
+	AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005	Jul	CAHN	
	HYDRALAZINE HYDROCHLORIDE							
	TABLET; ORAL							
	HYDRALAZINE HYDROCHLORIDE							
AA	HETERO LABS UNIT III	10MG	A040901	001	Sep 12, 2008	Jul	CAHN	
AA		25MG	A040901	002	Sep 12, 2008	Jul	CAHN	
AA		50MG	A040901	003	Sep 12, 2008	Jul	CAHN	
AA		100MG	A040901	004	Sep 12, 2008	Jul	CAHN	
	HYDROCHLOROTHIAZIDE							
	CAPSULE; ORAL							
	HYDROCHLOROTHIAZIDE							
AB	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN	
AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN	
	TABLET; ORAL							
	HYDROCHLOROTHIAZIDE							
>D> AB	ACTAVIS ELIZABETH	25MG	A085054	002		Aug	DISC	
>A>	@	25MG	A085054	002		Aug	DISC	
>D> AB		50MG	A085208	001		Aug	DISC	
>A>	@	50MG	A085208	001		Aug	DISC	
AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN	
AB		50MG	A040809	002	Sep 04, 2007	Jan	CAHN	
	HYDROCHLOROTHIAZIDE; IRBESARTAN							
	TABLET; ORAL							
	AVALIDE							
	@ SANOFI AVENTIS	12.5MG;75MG	N020758	001	Sep 30, 1997	Jun	CAHN	
		12.5MG;150MG	N020758	002	Sep 30, 1997	Jun	CAHN	
>D>		12.5MG;300MG	N020758	003	Aug 31, 1998	Aug	CRLD	

TABLET; ORAL
AVALIDE

>A>		+	SANOFI AVENTIS	12.5MG;300MG	N020758	003	Aug 31, 1998	Aug	CRLD
				12.5MG;300MG	N020758	003	Aug 31, 1998	Jun	CAHN
>D>		+		25MG;300MG	N020758	004	Mar 15, 2005	Aug	DISC
>A>			@	25MG;300MG	N020758	004	Mar 15, 2005	Aug	DISC
		+		25MG;300MG	N020758	004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB		PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002	Aug	CAHN
>A>	AB			12.5MG;20MG	A076230	002	Jul 01, 2002	Aug	CAHN
>A>	AB			25MG;20MG	A076230	003	Jul 01, 2002	Aug	CAHN
>D>	AB		PRINSTON PHARM LLC	12.5MG;10MG	A076230	001	Jul 01, 2002	Aug	CAHN
	AB			12.5MG;10MG	A076230	001	Jul 01, 2002	May	CAHN
>D>	AB			12.5MG;20MG	A076230	002	Jul 01, 2002	Aug	CAHN
	AB			12.5MG;20MG	A076230	002	Jul 01, 2002	May	CAHN
>D>	AB			25MG;20MG	A076230	003	Jul 01, 2002	Aug	CAHN
	AB			25MG;20MG	A076230	003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	AB		WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA
	AB			12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
	AB			25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	AB		INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Apr	NEWA
	AB			12.5MG;20MG	A201356	002	Apr 20, 2011	Apr	NEWA
	AB			25MG;20MG	A201356	003	Apr 20, 2011	Apr	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
REZIRA

		+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun	NEWA

HYDROCORTISONE

SOLUTION; TOPICAL
TEXACORT

>A>		+	STAYMA	2.5%	A081271	001	Apr 17, 1992	Aug	CAHN
>D>		+	TIBER LABS	2.5%	A081271	001	Apr 17, 1992	Aug	CAHN
		+		2.5%	A081271	001	Apr 17, 1992	May	CAHN

TABLET; ORAL
HYDROCORTISONE

	AB		COREPHARMA	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
	AB			10MG	A040646	002	Mar 30, 2007	Apr	CAHN
	AB			20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE

			@ FERA PHARMS	0.5%	A080828	001		Mar	CAHN

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

>D>		A-HYDROCORT						
>D>	AP	HOSPIRA	EQ 250MG BASE/VIAL	A085930	001		Aug	DISC
>A>		@	EQ 250MG BASE/VIAL	A085930	001		Aug	DISC
>D>	AP		EQ 500MG BASE/VIAL	A085931	001		Aug	DISC
>A>		@	EQ 500MG BASE/VIAL	A085931	001		Aug	DISC
>D>	AP		EQ 1GM BASE/VIAL	A085932	001		Aug	DISC
>A>		@	EQ 1GM BASE/VIAL	A085932	001		Aug	DISC

HYDROFLUMETHIAZIDE

TABLET; ORAL

		HYDROFLUMETHIAZIDE						
		@ PAR PHARM	50MG	A088850	001	May 31, 1985	May	DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

		HYDROMORPHONE HYDROCHLORIDE						
	AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

		CYANOKIT						
		@ MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

		PAREDRINE						
		@ PHARMICS	1%	N000004	004		Jan	CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

		MAKENA						
	+	KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Feb	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

		HYDROXYZINE HYDROCHLORIDE						
		@ ACTAVIS TOTOWA	10MG	A040600	001	Dec 28, 2004	Jul	DISC
		@	25MG	A040602	001	Dec 28, 2004	Jul	DISC
		@	50MG	A040604	001	Dec 28, 2004	Jul	DISC
	AB	HETERO LABS UNIT III	10MG	A040805	001	May 29, 2008	Jul	CAHN
	AB		25MG	A040805	002	May 29, 2008	Jul	CAHN
	AB		50MG	A040805	003	May 29, 2008	Jul	CAHN

IBUPROFEN

TABLET; ORAL

		IBUPROHM						
>D>	AB	OHM LABS	400MG	A070469	001	Aug 29, 1985	Aug	DISC
>A>		@	400MG	A070469	001	Aug 29, 1985	Aug	DISC

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

>D>			COMBUNOX							
>D>	AB	+	FOREST LABS	400MG;5MG	N021378	001	Nov 26, 2004	Aug	DISC
>A>			@	400MG;5MG	N021378	001	Nov 26, 2004	Aug	DISC
			OXYCODONE HYDROCHLORIDE AND IBUPROFEN							
>D>	AB		ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008	Aug	CRLD
>A>	AB	+		400MG;5MG	A078769	001	Jan 04, 2008	Aug	CRLD

>A> ICATIBANT ACETATE

>A> INJECTABLE; SUBCUTANEOUS

>A> FIRAZYR

>A>		+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Aug	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

	AP		SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

	AP		BEDFORD LABS	1GM/20ML(50MG/ML)	A076619	001	Jun 29, 2011	Jun	NEWA
	AP			3GM/60ML(50MG/ML)	A076619	002	Jun 29, 2011	Jun	NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

			NOVARTIS	2MG	N022192	002	May 06, 2009	Jan	CAHN
				4MG	N022192	003	May 06, 2009	Jan	CAHN
				6MG	N022192	004	May 06, 2009	Jan	CAHN
				8MG	N022192	005	May 06, 2009	Jan	CAHN
				10MG	N022192	006	May 06, 2009	Jan	CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

			@ ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Jun	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

			@ ACTAVIS TOTOWA	10MG	A040753	001	Feb 28, 2008	Jul	DISC
			@	25MG	A040752	001	Feb 28, 2008	Jul	DISC
			@	50MG	A040751	001	Feb 28, 2008	Jul	DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

	AB		TARO	5%	A200173	001	Apr 15, 2011	Apr	NEWA
	AB		TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	NEWA
	AB		TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

ZYCLARA

		+	GRACEWAY	2.5%	N022483	002	Jul 15, 2011	Jul	NEWA

INDACATEROL MALEATE

POWDER; INHALATION
ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jul	NEWA

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA
AB	HETERO LABS UNIT III	25MG	A091240	001	Apr 12, 2011	Jul	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB	+ SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS
DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200

@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250

>D>	AP	HOSPIRA	51%	A075005	001	Feb 24, 1998	Aug	DISC
>A>	@		51%	A075005	001	Feb 24, 1998	Aug	DISC
	@		51%	A074898	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300

>D>	AP	HOSPIRA	61%	A075005	002	Feb 24, 1998	Aug	DISC
>A>	@		61%	A075005	002	Feb 24, 1998	Aug	DISC
	@		61%	A074898	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	61%	A074637	001	Apr 03, 1997	Aug	DISC
>A>	@		61%	A074637	001	Apr 03, 1997	Aug	DISC
	@		61%	A074636	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370

>D>	AP	HOSPIRA	76%	A075005	003	Feb 24, 1998	Aug	DISC
>A>	@		76%	A075005	003	Feb 24, 1998	Aug	DISC
	@		76%	A074898	004	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

>D>	AN	ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999	Aug	DISC
>A>	@		0.02%	A075111	001	Apr 22, 1999	Aug	DISC
	AN	RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA
AP		X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	CAHN
AP			100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER

		LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL

AB		VALEANT INTL	5MG	N012093	007	Jul 29, 1988	Jun	CAHN
AB			10MG	N012093	002	Jul 29, 1988	Jun	CAHN
AB			20MG	N012093	006	Jul 29, 1988	Jun	CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Jun	CAHN
	+		40MG	N012093	001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB		TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011	May	NEWA
AB			60MG	A200495	001	Jun 03, 2011	May	NEWA
AB			120MG	A200495	002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL
ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX

		@ ORTHO MCNEIL JANSSEN	10MG/ML	N020966	001	Mar 30, 1999	May	DISC

TABLET; ORAL
ONMEL

	+	STIEFEL LABS INC	200MG	N022484	001	Apr 29, 2010	May	CTNA

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL
EXTINA

>D>		+	STIEFEL LABS INC	2%	N021738	001	Jun 12, 2007	Aug	CFTG
>A>	AT	+		2%	N021738	001	Jun 12, 2007	Aug	CFTG
>A>			KETOCONAZOLE						
>A>	AT		PERRIGO ISRAEL	2%	A091550	001	Aug 25, 2011	Aug	NEWA

GEL; TOPICAL
XOLEGEL

	+	AQUA PHARMS	2%	N021946	001	Jul 28, 2006	May	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP		PFIZER	15MG/ML	A078299	001	Jul 16, 2007	May	CAHN
AP			30MG/ML	A078299	002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL

SPRIX

	+	LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB	+	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG

LAMIVUDINE AND ZIDOVUDINE

AB		TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	May	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669	004	Apr 08, 2011	Mar	NEWA
AB		ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
AB			100MG	A090607	002	Jan 13, 2011	Jan	NEWA
AB			150MG	A090607	003	Jan 13, 2011	Jan	NEWA
AB			200MG	A090607	004	Jan 13, 2011	Jan	NEWA
AB		ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
AB			100MG	A090607	002	Jan 13, 2011	Apr	CAHN
AB			150MG	A090607	003	Jan 13, 2011	Apr	CAHN
AB			200MG	A090607	004	Jan 13, 2011	Apr	CAHN
AB		HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
AB			100MG	A078134	002	Apr 19, 2011	Apr	NEWA
AB			150MG	A078134	003	Apr 19, 2011	Apr	NEWA
AB			200MG	A078134	004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
AT		LUITPOLD	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
AT		PADDOCK LABS	0.005%	A090887	001	Jul 19, 2011	Jul	NEWA
AT		PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LETROZOLE

TABLET; ORAL
LETROZOLE

	AB	ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
>A>	AB	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Aug	CAHN
>D>	AB	AMIDE PHARM	2.5MG	A090292	001	Jul 13, 2011	Aug	CAHN
	AB		2.5MG	A090292	001	Jul 13, 2011	Jul	NEWA
	AB	DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
	AB	ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA
	AB	FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
	AB	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
	AB	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
	AB	KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
	AB	NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
	AB	ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA
	AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
		@ SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
	AB		2.5MG	A090196	001	Jun 03, 2011	May	NEWA
	AB	TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

		@ GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC

LUPRON DEPOT

	+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
	+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN
			45MG/VIAL	N020517	003	Jun 17, 2011	Jun	NEWA

LUPRON DEPOT-PED

>A>	+	ABBOTT ENDOCRINE	11.25MG/VIAL	N020263	007	Aug 15, 2011	Aug	NEWA
>A>	+		30MG/VIAL	N020263	008	Aug 15, 2011	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

>D>	AN	BREATH LTD	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug	CAHN
>D>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug	CAHN
>D>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug	CAHN
>A>	AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug	CAHN
>A>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug	CAHN
>A>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

	AP	INNOPHARMA LLC	500MG/ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	NEWA

SOLUTION; ORAL
LEVETIRACETAM

	AA	APOTEX	100MG/ML	A090187	001	Aug 05, 2011	Jul	NEWA

TABLET; ORAL
LEVETIRACETAM

	AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
	AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
	AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
	AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA

TABLET; ORAL
LEVETIRACETAM

	AB		AJANTA PHARMA	250MG		A201293	001	Jun 14, 2011	May NEWA
	AB			500MG		A201293	002	Jun 14, 2011	May NEWA
	AB			750MG		A201293	003	Jun 14, 2011	May NEWA
	AB			1GM		A201293	004	Jun 14, 2011	May NEWA
>A>	AB		BRECKENRIDGE PHARM	250MG		A090511	001	Aug 18, 2011	Aug NEWA
>A>	AB			500MG		A090511	002	Aug 18, 2011	Aug NEWA
>A>	AB			750MG		A090511	003	Aug 18, 2011	Aug NEWA
>A>	AB			1GM		A090511	004	Aug 18, 2011	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL
KEPPRA XR

>D>			UCB INC	500MG		N022285	001	Sep 12, 2008	Aug CFTG
>A>	AB			500MG		N022285	001	Sep 12, 2008	Aug CFTG
>D>		+		750MG		N022285	002	Feb 12, 2009	Aug CFTG
>A>	AB	+		750MG		N022285	002	Feb 12, 2009	Aug CFTG

LEVETIRACETAM

>A>	AB		ACTAVIS ELIZABETH	500MG		A091557	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091557	002	Sep 12, 2011	Aug NEWA
>A>	AB		APOTEX INC	500MG		A091261	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091261	002	Sep 12, 2011	Aug NEWA
>A>	AB		LUPIN LTD	500MG		A091399	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091399	002	Sep 12, 2011	Aug NEWA
>A>	AB		MUTUAL PHARM CO INC	500MG		A091285	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091285	002	Sep 12, 2011	Aug NEWA
>A>	AB		PAR PHARM	500MG		A091291	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091291	002	Sep 12, 2011	Aug NEWA
>A>	AB		TEVA PHARMS	500MG		A091430	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091430	002	Sep 12, 2011	Aug NEWA
>A>	AB		WATSON LABS FLORIDA	500MG		A091093	001	Sep 12, 2011	Aug NEWA
>A>	AB			750MG		A091093	002	Sep 12, 2011	Aug NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

	AB		DR REDDYS LABS LTD	5MG		A090392	001	Feb 24, 2011	Feb NEWA
	AB		GLENMARK GENERICS	5MG		A090385	001	Feb 24, 2011	Feb NEWA
>A>	AB		TEVA PHARMS	5MG		A090199	001	Aug 22, 2011	Aug NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVAQUIN

	AP	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)		N020635	001	Dec 20, 1996	Jun CFTG
	AP	+		EQ 750MG/30ML (EQ 25MG/ML)		N020635	004	Dec 20, 1996	Jun CFTG

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)		N020635	002	Dec 20, 1996	Jun CFTG
	AP	+		EQ 500MG/100ML (EQ 5MG/ML)		N020635	003	Dec 20, 1996	Jun CFTG
	AP	+		EQ 750MG/150ML (EQ 5MG/ML)		N020635	005	Dec 20, 1996	Jun CFTG

LEVOFLOXACIN

	AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)		A091644	001	Jun 20, 2011	Jun NEWA
	AP			EQ 750MG/30ML (EQ 25MG/ML)		A091644	002	Jun 20, 2011	Jun NEWA
	AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)		A200560	001	Jun 20, 2011	Jun NEWA
	AP			EQ 750MG/30ML (EQ 25MG/ML)		A200560	002	Jun 20, 2011	Jun NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP		ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)		A090343	001	Jul 07, 2011	Jun NEWA
	AP			EQ 500MG/100ML (EQ 5MG/ML)		A090343	002	Jul 07, 2011	Jun NEWA

	INJECTABLE; INJECTION							
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	ACS DOBFAR INFO SA	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jun	NEWA
	SOLUTION; ORAL							
	LEVAQUIN							
AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004	Jun	CFTG
	LEVOFLOXACIN							
AA	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Jun	NEWA
	SOLUTION/DROPS; OPHTHALMIC							
	LEVOFLOXACIN							
AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA
	TABLET; ORAL							
	LEVAQUIN							
AB	ORTHO MCNEIL JANSSEN	250MG	N020634	001	Dec 20, 1996	Jun	CFTG
AB		500MG	N020634	002	Dec 20, 1996	Jun	CFTG
AB	+	750MG	N020634	003	Sep 08, 2000	Jun	CFTG
	LEVOFLOXACIN							
AB	AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A201043	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A201043	003	Jun 20, 2011	Jun	NEWA
AB	DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076710	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076710	003	Jun 20, 2011	Jun	NEWA
AB	GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A200250	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A200250	003	Jun 20, 2011	Jun	NEWA
AB	LUPIN	250MG	A078424	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A078424	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A078424	003	Jun 20, 2011	Jun	NEWA
AB	MYLAN	250MG	A076276	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076276	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077097	001	Jun 20, 2011	Jun	NEWA
AB	SANDOZ	250MG	A077438	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A077438	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077438	003	Jun 20, 2011	Jun	NEWA
AB	TEVA	250MG	A076361	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076361	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076361	003	Jun 20, 2011	Jun	NEWA
AB	TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090722	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090722	003	Jun 20, 2011	Jun	NEWA
AB	WOCKHARDT	250MG	A090367	001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090367	002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090367	003	Jun 20, 2011	Jun	NEWA
	LEVOLEUCOVORIN CALCIUM							
	POWDER; IV (INFUSION)							
	FUSILEV							
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA
	SOLUTION; IV (INFUSION)							
	FUSILEV							
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR

SOLUTION; IV (INFUSION)
FUSILEV

+	SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL
PLAN B

	@ TEVA WOMENS	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
AB +		0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

	@ VALEANT PHARM INTL	2MG	N008720	001	Dec 19, 1991	Mar	DISC

LEVORPHANOL TARTRATE

	ROXANE	2MG	A074278	001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

+	APP PHARMS	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	NEWA
+		200MCG/VIAL	N202231	002	Jun 24, 2011	Jun	NEWA
+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	NEWA

TABLET; ORAL
LEVO-T

AB1, AB2, AB3	ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3	+	0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC

LIDOCAINE

OINTMENT; TOPICAL
LIDOCAINE

	AT		NOVOCOL INC	5%	A040911	001	May 23, 2011	May	NEWA

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
LIDOCAINE HYDROCHLORIDE

	AT		HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	Mar	NEWA

XYLOCAINE

>D>	AT	+	APP PHARMS	2%	N008816	001		Aug	CAHN
>A>	AT	+	OAK PHARMS	2%	N008816	001		Aug	CAHN

SOLUTION; ORAL
LIDOCAINE HYDROCHLORIDE VISCOUS

>D>	AT		ACTAVIS MID ATLANTIC	2%	A086578	001		Aug	DISC
>A>			@	2%	A086578	001		Aug	DISC

SOLUTION; TOPICAL
PEDIATRIC LTA KIT

>D>			HOSPIRA	2%	A085995	001		Aug	DISC
>A>			@	2%	A085995	001		Aug	DISC

SYSTEM; INTRADERMAL
ZINGO

			@ POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Jun	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
EMLA

>D>	AB	+	APP PHARMS	2.5%;2.5%	N019941	001	Dec 30, 1992	Aug	CAHN
>A>	AB	+	OAK PHARMS	2.5%;2.5%	N019941	001	Dec 30, 1992	Aug	CAHN

LINAGLIPTIN

TABLET; ORAL
TRADJENTA

		+	BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011	May	NEWA

LISINOPRIL

TABLET; ORAL
LISINOPRIL

>A>	AB		PRINSTON INC	2.5MG	A076180	001	Jul 01, 2002	Aug	CAHN
>A>	AB			5MG	A076180	002	Jul 01, 2002	Aug	CAHN
>A>	AB			10MG	A076180	003	Jul 01, 2002	Aug	CAHN
>A>	AB			20MG	A076164	001	Jul 01, 2002	Aug	CAHN
>A>	AB			30MG	A076164	002	Jul 01, 2002	Aug	CAHN
>A>	AB			40MG	A076164	003	Jul 01, 2002	Aug	CAHN
>D>	AB		PRINSTON PHARM LLC	2.5MG	A076180	001	Jul 01, 2002	Aug	CAHN
	AB			2.5MG	A076180	001	Jul 01, 2002	May	CAHN
>D>	AB			5MG	A076180	002	Jul 01, 2002	Aug	CAHN
	AB			5MG	A076180	002	Jul 01, 2002	May	CAHN
>D>	AB			10MG	A076180	003	Jul 01, 2002	Aug	CAHN
	AB			10MG	A076180	003	Jul 01, 2002	May	CAHN
>D>	AB			20MG	A076164	001	Jul 01, 2002	Aug	CAHN
	AB			20MG	A076164	001	Jul 01, 2002	May	CAHN
>D>	AB			30MG	A076164	002	Jul 01, 2002	Aug	CAHN
	AB			30MG	A076164	002	Jul 01, 2002	May	CAHN
>D>	AB			40MG	A076164	003	Jul 01, 2002	Aug	CAHN

TABLET; ORAL
LISINOPRIL

AB	PRINSTON PHARM LLC	40MG	A076164	003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LORAZEPAM

TABLET; ORAL
ATIVAN

AB	VALEANT INTL	0.5MG	N017794	001			Jul	CAHN
AB		1MG	N017794	002			Jul	CAHN
AB	+	2MG	N017794	003			Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428	001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428	002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428	003	Oct 06, 2010	Apr	CAHN
>D> AB	HUAHAI US INC	25MG	A091497	001	Jun 06, 2011	Aug	CAHN
AB		25MG	A091497	001	Jun 06, 2011	May	NEWA
>D> AB		50MG	A091497	002	Jun 06, 2011	Aug	CAHN
AB		50MG	A091497	002	Jun 06, 2011	May	NEWA
>D> AB		100MG	A091497	003	Jun 06, 2011	Aug	CAHN
AB		100MG	A091497	003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590	002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590	003	Oct 06, 2010	Jan	NEWA
>A> AB	PRINSTON INC	25MG	A091497	001	Jun 06, 2011	Aug	CAHN
>A> AB		50MG	A091497	002	Jun 06, 2011	Aug	CAHN
>A> AB		100MG	A091497	003	Jun 06, 2011	Aug	CAHN

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011	Apr	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION
>D> PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

>D>	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982	Aug	DISC
>A>	@	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982	Aug	DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451	002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451	003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659	002	Jun 04, 2010	Jan	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	LUPIN LTD	250MG	A091322	001	Jul 22, 2011	Jul	NEWA

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN
AB	PURACAP PHARM	7.5MG	A077938	001	Jul 19, 2006	Jun	CAHN
AB		15MG	A077938	002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

@	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	May	CAHN
@		10MG	A090058	002	May 05, 2010	May	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002	001	Jul 30, 1993	May	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	May	CAHN
AA		400MG	A090122	002	Feb 18, 2009	May	CAHN
AA	TARO	200MG	A200998	001	May 23, 2011	May	NEWA
AA		400MG	A200998	002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	May	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA

MERREM

AP +	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
AP +		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB +	MEDA PHARMS	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN

SFROWASA

AB	MEDA PHARMS	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

+	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL
ASACOL HD
\+ WARNER CHILCOTT LLC 800MG N021830 001 May 29, 2008 Jun CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE
AB MYLAN 500MG A075973 001 Jan 25, 2002 Feb CAHN
AB 850MG A075973 002 Jan 25, 2002 Feb CAHN
AB 1GM A075973 003 Jan 25, 2002 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL
FORTAMET
AB2 ANDRX LABS LLC 500MG N021574 001 Apr 27, 2004 Jun CTEC
AB + 1GM N021574 002 Apr 27, 2004 Jun CTEC
GLUCOPHAGE XR
AB1 BRISTOL MYERS SQUIBB 500MG N021202 001 Oct 13, 2000 Jun CTEC
METFORMIN HYDROCHLORIDE
>D> AB1 ACTAVIS ELIZABETH 500MG A076450 001 Oct 01, 2004 Aug DISC
>A> @ 500MG A076450 001 Oct 01, 2004 Aug DISC
AB1 500MG A076450 001 Oct 01, 2004 Jun CTEC
>D> AB 750MG A076878 001 Apr 13, 2005 Aug DISC
>A> @ 750MG A076878 001 Apr 13, 2005 Aug DISC
>A> AB1 ALVOGEN 500MG A078321 001 Apr 17, 2008 Aug CAHN
>A> AB 750MG A078321 002 Apr 17, 2008 Aug CAHN
AB1 AMNEAL PHARMS NY 500MG A078596 001 Jan 03, 2008 Jun CTEC
AB1 APOTEX 500MG A076706 001 Dec 14, 2004 Jun CTEC
AB 750MG A076706 002 Dec 29, 2005 Jun CAHN
AB1 IMPAX LABS 500MG A076249 001 Jul 30, 2004 Jun CTEC
>D> AB2 LUPIN LTD 500MG A090692 001 Jun 29, 2011 Aug CAHN
>A> AB2 500MG A090692 001 Jun 29, 2011 Aug CAHN
AB2 500MG A090692 001 Jun 29, 2011 Jun NEWA
>D> AB 1GM A090692 002 Jun 29, 2011 Aug CAHN
>A> AB 1GM A090692 002 Jun 29, 2011 Aug CAHN
AB 1GM A090692 002 Jun 29, 2011 Jun NEWA
AB1 MYLAN 500MG A076650 001 Sep 13, 2005 Jun CTEC
>D> AB1 NEUROSCI INC 500MG A078321 001 Apr 17, 2008 Aug CAHN
AB1 500MG A078321 001 Apr 17, 2008 Jun CTEC
>D> AB 750MG A078321 002 Apr 17, 2008 Aug CAHN
AB1 NOSTRUM 500MG A076756 001 Jul 26, 2006 Jun CTEC
AB1 RANBAXY LABS LTD 500MG A076413 001 Jun 18, 2004 Jun CTEC
AB1 SANDOZ 500MG A076873 001 Dec 14, 2004 Jun CTEC
AB1 SUN PHARM INDS (IN) 500MG A077336 001 Feb 09, 2006 Jun CTEC
AB1 TEVA 500MG A076269 001 Jun 18, 2004 Jun CTEC
AB1 TORRENT PHARM 500MG A090014 001 Dec 30, 2009 Jun CTEC
AB1 WATSON LABS FLORIDA 500MG A076172 001 Jun 16, 2004 Jun CTEC
AB1 WATSON LABS INC 500MG A076818 001 Dec 14, 2004 Jun CTEC
AB1 ZYDUS PHARMS USA 500MG A077060 001 Apr 20, 2005 Jun CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET
AB TAKEDA GLOBAL 500MG;EQ 15MG BASE N021842 001 Aug 29, 2005 Feb CFTG
AB + 850MG;EQ 15MG BASE N021842 002 Aug 29, 2005 Feb CFTG
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
AB MYLAN 500MG;EQ 15MG BASE A090406 001 Feb 25, 2011 Feb NEWA
AB 850MG;EQ 15MG BASE A090406 002 Feb 25, 2011 Feb NEWA

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

AB		EMCURE PHARMS USA	5MG	A040734	001	Dec 14, 2007	Jul	CAHN
AB			10MG	A040734	002	Dec 14, 2007	Jul	CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA		LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
AA			750MG	A084756	001		Jun	CAHN
		@ PURACAP PHARM	500MG	A084231	002		Jun	CAHN
		@	750MG	A084471	001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL
METHERGINE

AB	+	NOVARTIS	0.2MG	N006035	003		Apr	CTEC

METHYLERGONOVINE MALEATE

AB		NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002	Aug	DISC
>A>		@	5MG	A040321	001	Feb 05, 2002	Aug	DISC
>D>	AB		10MG	A040321	002	Feb 05, 2002	Aug	DISC
>A>		@	10MG	A040321	002	Feb 05, 2002	Aug	DISC
>D>	AB		20MG	A040321	003	Feb 05, 2002	Aug	DISC
>A>		@	20MG	A040321	003	Feb 05, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001	Aug	DISC
>A>		@	20MG	A075450	001	Dec 21, 2001	Aug	DISC

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP		HEMOFARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
AP			EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
		@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		MUSTAFA NEVSAT	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jul	NEWA
AP			EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jul	NEWA
AP			EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jul	NEWA

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP		MUSTAFA NEVSAT	EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jul	NEWA

SOLU-MEDROL

AP	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856	007	Feb 27, 1985	Jul	CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991	Aug	DISC
>A>		@	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991	Aug	DISC

TABLET; ORAL
REGLAN

>D>	AB	ALAVEN PHARM	EQ 5MG BASE	N017854	002	May 05, 1987	Aug	CAHN
>D>	AB	+	EQ 10MG BASE	N017854	001		Aug	CAHN
>A>	AB	ANI PHARMS	EQ 5MG BASE	N017854	002	May 05, 1987	Aug	CAHN
>A>	AB	+	EQ 10MG BASE	N017854	001		Aug	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
REGLAN ODT

>D>		@ ALAVEN PHARM	EQ 5MG BASE	N021793	001	Jun 10, 2005	Aug	CAHN
>D>		@	EQ 10MG BASE	N021793	002	Jun 10, 2005	Aug	CAHN
>A>		@ MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005	Aug	CAHN
>A>		@	EQ 10MG BASE	N021793	002	Jun 10, 2005	Aug	CAHN

METRONIDAZOLE

GEL; TOPICAL
METROGEL

AB	+	GALDERMA LABS LP	1%	N021789	001	Jun 30, 2005	Jul	CTEC

METRONIDAZOLE

AB		G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA
AB		TOLMAR	1%	A090903	001	Jul 22, 2011	Jul	NEWA

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	PFIZER	500MG/100ML	N018353	002		Jun	CAHN

TABLET; ORAL
METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	250MG	A079067	001	Mar 13, 2009	May	CAHN
AB			500MG	A079067	002	Mar 13, 2009	May	CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

		@ PFIZER	EQ 500MG BASE/VIAL	N018353	001		Jun	DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

		@ ORTHO JANSSEN	2%	N017494	001		Jul	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

		MIDAZOLAM HYDROCHLORIDE								
>D>	AP	HOSPIRA	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000	Aug	DISC		
>A>		@	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000	Aug	DISC		
		MIDOZALAM HYDROCHLORIDE								
	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	NEWA		
	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	NEWA		

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

		SAVELLA								
>D>		CYPRESS BIOSCIENCE	50MG	N022256	003	Jan 14, 2009	Aug	CRLD		
>A>		+	50MG	N022256	003	Jan 14, 2009	Aug	CRLD		
>D>		+	100MG	N022256	004	Jan 14, 2009	Aug	CRLD		
>A>			100MG	N022256	004	Jan 14, 2009	Aug	CRLD		

MILRINONE LACTATE

INJECTABLE; INJECTION

		MILRINONE LACTATE								
		@ HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC		

MIRTAZAPINE

TABLET; ORAL

		MIRTAZAPINE								
>D>	AB	ACTAVIS ELIZABETH	15MG	A076308	001	Jun 20, 2003	Aug	DISC		
>A>		@	15MG	A076308	001	Jun 20, 2003	Aug	DISC		
>D>	AB		30MG	A076308	002	Jun 20, 2003	Aug	DISC		
>A>		@	30MG	A076308	002	Jun 20, 2003	Aug	DISC		
>D>	AB		45MG	A076308	003	Jun 20, 2003	Aug	DISC		
>A>		@	45MG	A076308	003	Jun 20, 2003	Aug	DISC		
		@ ACTAVIS TOTOWA	15MG	A076241	001	Jun 25, 2003	Jul	DISC		
		@	30MG	A076241	002	Jun 25, 2003	Jul	DISC		
		@	45MG	A076241	003	Jun 25, 2003	Jul	DISC		

TABLET, ORALLY DISINTEGRATING; ORAL

		MIRTAZAPINE								
	AB	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA		
	AB		30MG	A077959	002	Feb 14, 2011	Jan	NEWA		
	AB		45MG	A077959	003	Feb 14, 2011	Jan	NEWA		
		@ ACTAVIS TOTOWA	15MG	A076689	001	Aug 31, 2005	Jul	DISC		
		@	30MG	A076689	002	Aug 31, 2005	Jul	DISC		
		@	45MG	A076689	003	Aug 31, 2005	Jul	DISC		

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

		MITOXANTRONE HYDROCHLORIDE								
>D>	AP	HOSPIRA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871	001	Apr 11, 2006	Aug	CRLD		
>A>	AP	+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871	001	Apr 11, 2006	Aug	CRLD		
>D>	AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871	002	Apr 11, 2006	Aug	CRLD		
>A>	AP	+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871	002	Apr 11, 2006	Aug	CRLD		
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871	003	Apr 11, 2006	Aug	CRLD		

			INJECTABLE; INJECTION							
			MITOXANTRONE HYDROCHLORIDE							
>A>	AP	+	HOSPIRA	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871	003	Apr 11, 2006	Aug	CRLD
>D>			NOVANTRONE							
>D>	AP	+	EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987	Aug	DISC
>A>			@	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987	Aug	DISC
			MORPHINE SULFATE							
			INJECTABLE, LIPOSOMAL; EPIDURAL							
			DEPODUR							
		+	EKR THERAP	10MG/ML (10MG/ML)	N021671	001	May 18, 2004	May	CRLD
			@	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004	May	DISC
			SOLUTION; ORAL							
			MORPHINE SULFATE							
			LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011	Jun	NEWA
	AA		MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Jul	NEWA
>D>		+	ROXANE	100MG/5ML	N022195	003	Jan 25, 2010	Aug	CTEC
>A>	AA	+		100MG/5ML	N022195	003	Jan 25, 2010	Aug	CTEC
			TABLET, EXTENDED RELEASE; ORAL							
			MORPHINE SULFATE							
>D>	AB		WATSON LABS	100MG	A075656	001	Jan 30, 2001	Aug	DISC
>A>			@	100MG	A075656	001	Jan 30, 2001	Aug	DISC
			MUPIROCIN							
			OINTMENT; TOPICAL							
			MUPIROCIN							
	AB		GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011	May	NEWA
			MUPIROCIN CALCIUM							
			CREAM; TOPICAL							
			BACTROBAN							
		+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR
			NABUMETONE							
			TABLET; ORAL							
			NABUMETONE							
>D>	AB		ACTAVIS ELIZABETH	500MG	A079093	001	Feb 27, 2009	Aug	DISC
>A>			@	500MG	A079093	001	Feb 27, 2009	Aug	DISC
>D>	AB			750MG	A079093	002	Feb 27, 2009	Aug	DISC
>A>			@	750MG	A079093	002	Feb 27, 2009	Aug	DISC
	AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
	AB			750MG	A090445	002	Jan 12, 2011	Jan	NEWA
	AB		WATSON LABS	500MG	A091083	001	Jun 13, 2011	May	NEWA
	AB			750MG	A091083	002	Jun 13, 2011	May	NEWA
			NAFCILLIN SODIUM							
			INJECTABLE; INJECTION							
			NAFCILLIN SODIUM							
	AP		IBI	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Jun	NEWA
	AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Jun	NEWA
	AP		INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Apr	NEWA
	AP	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	50MG	A091205	001	Aug 17, 2011	Aug	NEWA
	AB	ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL
NAPROXEN

>A>	AB	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Aug	NEWA
>A>	AB		375MG	A091305	002	Aug 24, 2011	Aug	NEWA
>A>	AB		500MG	A091305	003	Aug 24, 2011	Aug	NEWA
	AB	MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
	AB		375MG	A091416	002	Feb 14, 2011	Jan	NEWA
	AB		500MG	A091416	003	Feb 14, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

>D>	AB	ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998	Aug	DISC
>A>		@	375MG	A074936	001	Feb 24, 1998	Aug	DISC
>D>	AB		500MG	A074936	002	Feb 24, 1998	Aug	DISC
>A>		@	500MG	A074936	002	Feb 24, 1998	Aug	DISC

NARATRIPTAN

TABLET; ORAL
NARATRIPTAN

	AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Apr	NEWA
	AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Apr	NEWA
	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
NARATRIPTAN

	AB	INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
	AB		EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

	AB	WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
	AB		120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL
VIRAMUNE XR

	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR

		@ EKR THERAP	45MG	N020005	002	Feb 21, 1992	May	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

	AB1	VALEANT INTL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

AB2		VALEANT INTL	30MG	A075289	002	Feb 06, 2001	Apr	CAHN
AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL
TASIGNA

>A>		NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010	Aug	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Apr	CFTG

NITROFURANTOIN

AB		AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

	+	PROSTRAKAN INC	0.4%	N021359	001	Jun 21, 2011	Jun	NEWA

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

AB		GLENMARK GENERICS	150MG	A090618	001	Jul 15, 2011	Jul	NEWA
AB			300MG	A090618	002	Jul 15, 2011	Jul	NEWA
AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NORGESTREL

TABLET; ORAL
OVRETTE

>A>		@ WYETH PHARMS	0.075MG	N017031	001		Aug	CAHN
>D>		@ WYETH PHARMS INC	0.075MG	N017031	001		Aug	CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
PAMELOR

>A>	AB	MALLINCKRODT LLC	EQ 10MG BASE	N018013	001		Aug	CAHN
>A>	AB		EQ 25MG BASE	N018013	002		Aug	CAHN

CAPSULE; ORAL
PAMELOR

>A>	AB		MALLINCKRODT LLC	EQ 50MG BASE	N018013	004		Aug	CAHN
>A>	AB	+		EQ 75MG BASE	N018013	003		Aug	CAHN
>D>	AB		TYCO HLTHCARE	EQ 10MG BASE	N018013	001		Aug	CAHN
>D>	AB			EQ 25MG BASE	N018013	002		Aug	CAHN
>D>	AB			EQ 50MG BASE	N018013	004		Aug	CAHN
>D>	AB	+		EQ 75MG BASE	N018013	003		Aug	CAHN

SOLUTION; ORAL
PAMELOR

	AA		MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012	001		Jul	CAHN

NYSTATIN

CREAM; TOPICAL
MYCOSTATIN

>D>									
>D>	AT	+	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575	001		Aug	DISC
>A>			@	100,000 UNITS/GM	A060575	001		Aug	DISC

NYSTATIN

>D>	AT		TARO	100,000 UNITS/GM	A064022	001	Jan 29, 1993	Aug	CRLD
>A>	AT			100,000 UNITS/GM	A064022	001	Jan 29, 1993	Aug	CRLD

POWDER; TOPICAL
MYCOSTATIN

>D>									
>D>	AT	+	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578	001		Aug	DISC
>A>			@	100,000 UNITS/GM	A060578	001		Aug	DISC

NYSTATIN

>D>	AT		COASTAL PHARMS	100,000 UNITS/GM	A065203	001	Jul 15, 2004	Aug	CRLD
>A>	AT			100,000 UNITS/GM	A065203	001	Jul 15, 2004	Aug	CRLD

SUSPENSION; ORAL
NYSTATIN

>D>	AA		BAUSCH AND LOMB	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Aug	CAHN
>A>	AA		HI TECH PHARMA	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Aug	CAHN
	AA		VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYKACET

>D>									
>D>	AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Aug	DISC
>A>			@	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Aug	DISC

OINTMENT; TOPICAL
MYKACET

>D>									
>D>	AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Aug	DISC
>A>			@	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Aug	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

	AP		WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Apr	NEWA
	AP			EQ 1MG BASE/ML	A090986	002	May 11, 2011	Apr	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

>D>	AP		BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
>D>	AP			EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
>D>	AP			EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Aug	CAHN
	AP			EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA
>A>	AP		MYLAN INSTITUTIONAL	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Aug	CAHN

		INJECTABLE; INJECTION							
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
>A>	AP	MYLAN INSTITUTIONAL	EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Aug	CAHN
>A>	AP		EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Aug	CAHN
	AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Apr	NEWA
	AP		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Apr	NEWA
	AP		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Apr	NEWA
		ONDANSETRON							
		TABLET, ORALLY DISINTEGRATING; ORAL							
		ONDANSETRON							
	AB	RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
	AB		8MG	A078602	002	Feb 24, 2011	Feb	NEWA
		ONDANSETRON HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		ONDANSETRON HYDROCHLORIDE							
	AP	PFIZER	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN
	AP	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD
		ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER							
	AP +	HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD
>D>	AP	TEVA PARENTERAL	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006	Aug	CAHN
>A>	AP	TEVA PHARMS	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006	Aug	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
	AP	PFIZER	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	May	CAHN
		SOLUTION; ORAL							
		ONDANSETRON HYDROCHLORIDE							
	AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
	AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA
		TABLET; ORAL							
		ONDANSETRON HYDROCHLORIDE							
	AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
	AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
	AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA
		ORPHENADRINE CITRATE							
		INJECTABLE; INJECTION							
		ORPHENADRINE CITRATE							
>A>	AP	SAGENT PHARMS	30MG/ML	A090585	001	Aug 30, 2011	Aug	NEWA
		OSELTAMIVIR PHOSPHATE							
		FOR SUSPENSION; ORAL							
		TAMIFLU							
		ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jun	NEWA
		@	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000	Jul	DISC
		OXALIPLATIN							
		INJECTABLE; IV (INFUSION)							
		OXALIPLATIN							
	AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
	AP		50MG/VIAL	A090849	001	Apr 28, 2011	Apr	NEWA
	AP		100MG/VIAL	A090849	002	Apr 28, 2011	Apr	NEWA
	AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>D>	AB	ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001	Aug	DISC
>A>		@	600MG	A075843	001	Oct 03, 2001	Aug	DISC
	AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXECTA

		KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011	Jun	NEWA
			7.5MG	N202080	002	Jun 17, 2011	Jun	NEWA

OXYCODONE HYDROCHLORIDE

	AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
	AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
	AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
	AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
	AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA
	AB		15MG	A091490	003	Mar 09, 2011	Feb	NEWA
	AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
	AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

	+	MEDA PHARMS	50MG	N016848	001		May	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

	AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
	AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

		@ ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
		@	15MG	N021610	006	Feb 29, 2008	Feb	DISC

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul	CAHN
			3MG	N021999	001	Dec 19, 2006	Jul	CAHN
	+		6MG	N021999	002	Dec 19, 2006	Jul	CAHN
			9MG	N021999	003	Dec 19, 2006	Jul	CAHN
		@	12MG	N021999	004	Dec 19, 2006	Jul	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

		JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CAHN
			78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CAHN
>D>			117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Aug	CRLD
>A>	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Aug	CRLD
			117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CAHN
			156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CAHN

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

>D>		+	JANSSEN PHARMS	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Aug	CRLD
>A>				234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Aug	CRLD
		+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP		AKORN STRIDES	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Aug	CAHN
>D>	AP			90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Aug	CAHN
	AP		MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May	CAHN
	AP			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May	CAHN
>A>	AP		PFIZER	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Aug	CAHN
>A>	AP			90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Aug	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

			JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010	Jun	CAHN
				43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010	Jun	CAHN
				70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010	Jun	CAHN
		+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

	AB		ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
	AB		DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA
>A>	AB		JUBILANT ORGANOSYS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Aug	NEWA
>A>	AB			EQ 40MG BASE	A090901	002	Aug 30, 2011	Aug	NEWA
	AB		KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
	AB		MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
	AB		TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
	AB		WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
	AB			EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

	AP		SANDOZ CANADA INC	0.002MG/ML	A091108	001	Jul 27, 2011	Jul	NEWA
	AP			0.005MG/ML	A091108	002	Jul 27, 2011	Jul	NEWA

ZEMPLAR

	AP	+	ABBOTT	0.002MG/ML	N020819	002	Feb 01, 2000	Jul	CFTG
	AP	+		0.005MG/ML	N020819	001	Apr 17, 1998	Jul	CFTG

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN

>A>		@ KING PFIZER	EQ 250MG BASE	A062310	001			Aug	CAHN
>D>		@ MONARCH PHARMS	EQ 250MG BASE	A062310	001			Aug	CAHN
		@	EQ 250MG BASE	A062310	001			May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAROXETINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968	001	Jun 21, 2010		Aug	DISC
>A>		@	EQ 10MG BASE	A076968	001	Jun 21, 2010		Aug	DISC
>D>	AB		EQ 20MG BASE	A076968	002	Jun 21, 2010		Aug	DISC
>A>		@	EQ 20MG BASE	A076968	002	Jun 21, 2010		Aug	DISC
>D>	AB		EQ 30MG BASE	A076968	003	Jun 21, 2010		Aug	DISC
>A>		@	EQ 30MG BASE	A076968	003	Jun 21, 2010		Aug	DISC
>D>	AB		EQ 40MG BASE	A076968	004	Jun 21, 2010		Aug	DISC
>A>		@	EQ 40MG BASE	A076968	004	Jun 21, 2010		Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

	AB	MYLAN	EQ 37.5MG BASE	A091427	001	Apr 14, 2011		Apr	NEWA

PAXIL CR

	AB	+ GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000		Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

	AB	VALEANT INTL	400MG	A075028	001	Jul 20, 1998		Apr	CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

>D>	AA	EMCURE PHARMS USA	35MG	A040762	001	Jan 28, 2008		Aug	CAHN
	AA		35MG	A040762	001	Jan 28, 2008		Jul	CAHN
>A>	AA	MIKAH PHARMA	35MG	A040762	001	Jan 28, 2008		Aug	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	15MG	A040460	001	Jan 14, 2003		Jul	DISC
		@	30MG	A040227	001	Jun 18, 1997		Jul	DISC
		@	30MG	A040448	001	Jan 22, 2003		Jul	DISC
		@	37.5MG	A040228	001	Jun 19, 1997		Jul	DISC
	AA	LANNETT HOLDINGS INC	37.5MG	A201961	001	Jul 20, 2011		Jul	NEWA

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	37.5MG	A040190	001	May 30, 1997		Jul	DISC
	AA	ELITE LABS	37.5MG	A200272	001	Jan 31, 2011		May	CAHN
	AA	EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011		Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

		CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011		Jun	NEWA
	+		30MG	N202088	002	Jun 13, 2011		Jun	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

		LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jul	NEWA
			EQ 30MG BASE	A040872	002	Jul 28, 2011	Jul	NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
ORAVERSE

>D>	+	NOVALAR	0.4MG/1.7ML	N022159	001	May 09, 2008	Aug	CAHN
>A>	+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008	Aug	CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP		X-GEN PHARMS	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON

>D>		@ ATON	1MG/0.5ML	N012223	002		Aug	CAHN
>D>		@	10MG/ML	N012223	001		Aug	CAHN
>A>		@ BIOVAIL TECHNOLOGIES	1MG/0.5ML	N012223	002		Aug	CAHN
>A>		@	10MG/ML	N012223	001		Aug	CAHN

TABLET; ORAL
MEPHYTON

>D>	+	ATON	5MG	N010104	003		Aug	CAHN
>A>	+	BIOVAIL TECHNOLOGIES	5MG	N010104	003		Aug	CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
ISOPTO CARPINE

		ALCON RES	1%	N200890	001	Jun 22, 2010	May	CTNA
			2%	N200890	002	Jun 22, 2010	May	CTNA
	+		4%	N200890	003	Jun 22, 2010	May	CTNA

PIMECROLIMUS

CREAM; TOPICAL
ELIDEL

	+	VALEANT INTL	1%	N021302	001	Dec 13, 2001	Jul	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		AUROBINDO PHARMA LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	May	NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	May	NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	May	NEWA
AP		HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	May	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	May	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@	MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN
@		20MG	A074043	002	Sep 22, 1992	Feb	CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

	KOWA CO	EQ 1MG BASE	N022363	001	Aug 03, 2009	Jul	CAHN
		EQ 2MG BASE	N022363	002	Aug 03, 2009	Jul	CAHN
+		EQ 4MG BASE	N022363	003	Aug 03, 2009	Jul	CAHN

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

AT	PRECISION DERMAT	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@	MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jun	CAHN
@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	DISC
AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jun	CAHN
		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jun	CAHN
AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jun	CAHN
@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jun	CAHN

COLYTE WITH FLAVOR PACKS

AA	+ MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jun	CAHN

COLYTE-FLAVORED

AA	+ MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jun	CAHN
AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jun	CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP	SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Jun	NEWA

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

>D>		@ PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Aug	CMFD
>A>			75MG/VIAL	N020451	001	Dec 27, 1995	Aug	CMFD
		@	75MG/VIAL	N020451	001	Dec 27, 1995	Jun	DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

>D>	AB	KV PHARM	8MEQ	N018238	001		Aug	CAHN
>A>	AB	NESHER PHARMS	8MEQ	N018238	001		Aug	CAHN

MICRO-K 10

>D>	AB	KV PHARM	10MEQ	N018238	002	May 14, 1984	Aug	CAHN
>A>	AB	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Aug	CAHN

POTASSIUM CHLORIDE

	AB	PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA
	AB		10MEQ	A200185	002	May 18, 2011	May	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

		BOEHRINGER INGELHEIM	2.25MG	N022421	006	Jun 17, 2011	Jun	NEWA
			3.75MG	N022421	007	Jun 17, 2011	Jun	NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

		@ VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

	AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
	AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
	AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
	AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

	AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
	AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

	AP	X-GEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	May	CAHN
	AP		50MG/ML	A040737	002	Apr 24, 2008	May	CAHN

SUPPOSITORY; RECTAL

PHENERGAN

>A>		@ SHIONOGI INC	12.5MG	N010926	002		Aug	CAHN
>A>		@	25MG	N010926	001		Aug	CAHN
>A>		@	50MG	N011689	001		Aug	CAHN
>D>		@ VICTORY PHARMA	12.5MG	N010926	002		Aug	CAHN

		SUPPOSITORY; RECTAL							
		PHENERGAN							
>D>		@ VICTORY PHARMA	25MG	N010926	001			Aug	CAHN
>D>		@	50MG	N011689	001			Aug	CAHN
		TABLET; ORAL							
		PROMETHAZINE HYDROCHLORIDE							
	AB	EMCURE PHARMS USA	12.5MG	A040673	001	Mar 05, 2008		Jul	CAHN
	AB		25MG	A040673	002	Mar 05, 2008		Jul	CAHN
	AB		50MG	A040673	003	Mar 05, 2008		Jul	CAHN
>A>	AB	MYLAN	12.5MG	A091054	001	Aug 30, 2011		Aug	NEWA
>A>	AB		25MG	A091054	002	Aug 30, 2011		Aug	NEWA
>A>	AB		50MG	A091054	003	Aug 30, 2011		Aug	NEWA
		PROPANTHELINE BROMIDE							
		TABLET; ORAL							
		PROPANTHELINE BROMIDE							
	+	ROXANE	15MG	A080927	002			Jan	CMFD
		PROPOXYPHENE HYDROCHLORIDE							
		CAPSULE; ORAL							
		DARVON							
		@ XANODYNE PHARM	65MG	N010997	003			Jan	DISC
>D>		DOLENE							
>D>	AA	HERITAGE PHARMS INC	65MG	A080530	001			Aug	DISC
>A>		@	65MG	A080530	001			Aug	DISC
>D>		PROPOXYPHENE HYDROCHLORIDE							
>D>	AA	MYLAN	65MG	A040569	001	Dec 16, 2004		Aug	DISC
>A>		@	65MG	A040569	001	Dec 16, 2004		Aug	DISC
		@ TEVA	65MG	A088615	001	Oct 22, 1984		Mar	DISC
		@ VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009		Mar	DISC
		@ WEST WARD	65MG	A083501	001			Jan	DISC
		PROPOXYPHENE NAPSYLATE							
		TABLET; ORAL							
		DARVON-N							
		@ XANODYNE PHARM	100MG	N016862	002			Jan	DISC
		PROPRANOLOL HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		PROPRANOLOL HYDROCHLORIDE							
	AB	GLAXOSMITHKLINE	60MG	A078703	001	Jul 15, 2011		Jul	NEWA
	AB		80MG	A078703	002	Jul 15, 2011		Jul	NEWA
	AB		120MG	A078703	003	Jul 15, 2011		Jul	NEWA
	AB		160MG	A078703	004	Jul 15, 2011		Jul	NEWA
	AB	ZYDUS PHARMS USA INC	60MG	A090321	001	Mar 25, 2011		Mar	NEWA
	AB		80MG	A090321	002	Mar 25, 2011		Mar	NEWA
	AB		120MG	A090321	003	Mar 25, 2011		Mar	NEWA
	AB		160MG	A090321	004	Mar 25, 2011		Mar	NEWA
		TABLET; ORAL							
		PROPRANOLOL HYDROCHLORIDE							
	AB	MYLAN	60MG	A070213	005	Apr 08, 2011		Mar	NEWA
		PYRIMETHAMINE							
		TABLET; ORAL							
		DARAPRIM							
	+	COREPHARMA	25MG	N008578	001			Jun	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

	@ ACTAVIS TOTOWA	EQ 5MG BASE	A076459	001	Dec 22, 2004	Jul	DISC
	@	EQ 10MG BASE	A076459	002	Dec 22, 2004	Jul	DISC
	@	EQ 20MG BASE	A076459	003	Dec 22, 2004	Jul	DISC
	@	EQ 40MG BASE	A076459	004	Dec 22, 2004	Jul	DISC
AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

>D> AB	ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008	Aug	DISC
>A>	@	1.25MG	A077513	001	Jun 18, 2008	Aug	DISC
>D> AB		2.5MG	A077513	002	Jun 18, 2008	Aug	DISC
>A>	@	2.5MG	A077513	002	Jun 18, 2008	Aug	DISC
>D> AB		5MG	A077513	003	Jun 18, 2008	Aug	DISC
>A>	@	5MG	A077513	003	Jun 18, 2008	Aug	DISC
>D> AB		10MG	A077513	004	Jun 18, 2008	Aug	DISC
>A>	@	10MG	A077513	004	Jun 18, 2008	Aug	DISC
AB	AUROBINDO PHARMA LTD	1.25MG	A091604	001	Jun 08, 2011	May	NEWA
AB		2.5MG	A091604	002	Jun 08, 2011	May	NEWA
AB		5MG	A091604	003	Jun 08, 2011	May	NEWA
AB		10MG	A091604	004	Jun 08, 2011	May	NEWA

TABLET; ORAL
RAMIPRIL

AB	MATRIX LABS LTD	1.25MG	A090650	001	Jun 30, 2011	Jun	NEWA
AB		2.5MG	A090650	002	Jun 30, 2011	Jun	NEWA
AB		5MG	A090650	003	Jun 30, 2011	Jun	NEWA
AB		10MG	A090650	004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

	@ MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
	@	EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	Mar	NEWA
AA	TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May	NEWA

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023	002	Aug 22, 1997	Feb	CAHN

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

	@ ACTAVIS TOTOWA	300MG	N050429	001		Jul	DISC

INJECTABLE; INJECTION
RIFAMPIN

AP	PFIZER	600MG/VIAL	A065421	001	May 22, 2008	May	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN

	+	SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

	+	TIBOTEC	EQ 25MG BASE	N202022	001	May 20, 2011	May	NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	100MG	A076375	001	Jan 14, 2003	Jul	DISC

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
RISPERDAL CONSTA

		JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jun	CAHN
	+		25MG/VIAL	N021346	001	Oct 29, 2003	Jun	CAHN
			37.5MG/VIAL	N021346	002	Oct 29, 2003	Jun	CAHN
			50MG/VIAL	N021346	003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL
RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996	Jun	CAHN

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011	May	NEWA
AA		TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL
RISPERDAL

AB		JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999	Jun	CAHN
AB			0.5MG	N020272	007	Jan 27, 1999	Jun	CAHN
AB	+		1MG	N020272	001	Dec 29, 1993	Jun	CAHN
AB			2MG	N020272	002	Dec 29, 1993	Jun	CAHN
AB			3MG	N020272	003	Dec 29, 1993	Jun	CAHN
AB			4MG	N020272	004	Dec 29, 1993	Jun	CAHN
	@		5MG	N020272	005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

	@	ACTAVIS TOTOWA	0.25MG	A078071	001	Jun 17, 2009	Jul	DISC
	@		0.5MG	A078071	002	Jun 17, 2009	Jul	DISC
	@		1MG	A078071	003	Jun 17, 2009	Jul	DISC
	@		2MG	A078071	004	Jun 17, 2009	Jul	DISC
	@		3MG	A078071	005	Jun 17, 2009	Jul	DISC
	@		4MG	A078071	006	Jun 17, 2009	Jul	DISC
>A>	AB	AJANTA PHARMA LTD	0.25MG	A201003	001	Aug 24, 2011	Aug	NEWA
>A>	AB		0.5MG	A201003	002	Aug 24, 2011	Aug	NEWA
>A>	AB		1MG	A201003	003	Aug 24, 2011	Aug	NEWA
>A>	AB		2MG	A201003	004	Aug 24, 2011	Aug	NEWA
>A>	AB		3MG	A201003	005	Aug 24, 2011	Aug	NEWA
>A>	AB		4MG	A201003	006	Aug 24, 2011	Aug	NEWA
	AB	CIPLA	0.25MG	A077543	001	May 18, 2011	May	NEWA
	AB		0.5MG	A077543	002	May 18, 2011	May	NEWA
	AB		1MG	A077543	003	May 18, 2011	May	NEWA
	AB		2MG	A077543	004	May 18, 2011	May	NEWA
	AB		3MG	A077543	005	May 18, 2011	May	NEWA

TABLET; ORAL
RISPERIDONE

AB		CIPLA	4MG	A077543	006	May 18, 2011	May	NEWA
	@	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
	@		0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
	@		1MG	A077784	003	Jun 08, 2010	Feb	DISC
	@		2MG	A077784	004	Jun 08, 2010	Feb	DISC
	@		3MG	A077784	005	Jun 08, 2010	Feb	DISC
	@		4MG	A077784	006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

AB		JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Jul	CAHN
AB	+		1MG	N021444	002	Apr 02, 2003	Jul	CAHN
AB			2MG	N021444	003	Apr 02, 2003	Jul	CAHN
AB			3MG	N021444	004	Dec 23, 2004	Jul	CAHN
AB			4MG	N021444	005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

AB		MYLAN	0.5MG	A091537	001	Mar 30, 2011	Mar	NEWA
AB			1MG	A091537	002	Mar 30, 2011	Mar	NEWA
AB			2MG	A091537	003	Mar 30, 2011	Mar	NEWA
AB			3MG	A091537	004	Mar 30, 2011	Mar	NEWA
AB			4MG	A091537	005	Mar 30, 2011	Mar	NEWA
AB		WATSON LABS FLORIDA	0.5MG	A076996	001	Apr 19, 2011	Apr	NEWA
AB			1MG	A076996	002	Apr 19, 2011	Apr	NEWA
AB			2MG	A076996	003	Apr 19, 2011	Apr	NEWA
AB			3MG	A076996	004	Apr 19, 2011	Apr	NEWA
AB			4MG	A076996	005	Apr 19, 2011	Apr	NEWA

RIVAROXABAN

TABLET; ORAL
XARELTO

	+	JOHNSON AND JOHNSON	10MG	N022406	001	Jul 01, 2011	Jul	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP		SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
AP			100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL
DALIRESP

	+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>A>	AB	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Aug	CAHN
>A>	AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	Aug	CAHN
>A>	AB		EQ 1MG BASE	A078110	003	May 05, 2008	Aug	CAHN
>A>	AB		EQ 2MG BASE	A078110	004	May 05, 2008	Aug	CAHN
>A>	AB		EQ 3MG BASE	A078110	005	May 05, 2008	Aug	CAHN
>A>	AB		EQ 4MG BASE	A078110	006	May 05, 2008	Aug	CAHN
>D>	AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Aug	CAHN
	AB		EQ 0.25MG BASE	A078110	001	May 05, 2008	May	CAHN
>D>	AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	Aug	CAHN

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

	AB	PRINSTON PHARM LLC	EQ 0.5MG BASE	A078110	002	May 05, 2008	May	CAHN
>D>	AB		EQ 1MG BASE	A078110	003	May 05, 2008	Aug	CAHN
	AB		EQ 1MG BASE	A078110	003	May 05, 2008	May	CAHN
>D>	AB		EQ 2MG BASE	A078110	004	May 05, 2008	Aug	CAHN
	AB		EQ 2MG BASE	A078110	004	May 05, 2008	May	CAHN
>D>	AB		EQ 3MG BASE	A078110	005	May 05, 2008	Aug	CAHN
	AB		EQ 3MG BASE	A078110	005	May 05, 2008	May	CAHN
>D>	AB		EQ 4MG BASE	A078110	006	May 05, 2008	Aug	CAHN
	AB		EQ 4MG BASE	A078110	006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL
BANZEL

	+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Mar	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM

	+	MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983	Jan	CAHN
	+		100MG	A086101	002	Oct 03, 1983	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

>D>	AT	ACTAVIS MID ATLANTIC	2.5%	A084394	001		Aug	DISC
>A>		@	2.5%	A084394	001		Aug	DISC

SERTACONAZOLE NITRATE

CREAM; TOPICAL
ERTACZO

	+	ORTHO JANSSEN	2%	N021385	001	Dec 10, 2003	Jul	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
SERTRALINE HYDROCHLORIDE

		@ ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

		@ ACTAVIS TOTOWA	EQ 25MG BASE	A078175	001	Jul 21, 2010	Jul	DISC
		@	EQ 50MG BASE	A078175	002	Jul 21, 2010	Jul	DISC
		@	EQ 100MG BASE	A078175	003	Jul 21, 2010	Jul	DISC
		@ IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
		@	EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
		@	EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
	AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
	AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
		@ PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299	001	Feb 06, 2007	Jul	DISC
		@	EQ 50MG BASE	A077299	002	Feb 06, 2007	Jul	DISC
		@	EQ 100MG BASE	A077299	003	Feb 06, 2007	Jul	DISC
		@ ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
		@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
		@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

		@ ACTAVIS TOTOWA	5MG		A078735	001	Aug 30, 2010	Jul	DISC
		@	10MG		A078735	002	Aug 30, 2010	Jul	DISC
		@	20MG		A078735	003	Aug 30, 2010	Jul	DISC
		@	40MG		A078735	004	Aug 30, 2010	Jul	DISC
		@	80MG		A078735	005	Aug 30, 2010	Jul	DISC

SINECATECHINS

OINTMENT; TOPICAL
VEREGEN

	+	MEDIGENE AG	15%		N021902	001	Oct 31, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

>D>		@ LAFAYETTE PHARMS	460MG/GM;420MG/GM		N018509	001	Aug 07, 1985	Aug	CAHN
>A>		@ MALLINCKRODT LLC	460MG/GM;420MG/GM		N018509	001	Aug 07, 1985	Aug	CAHN

SODIUM CHLORIDE

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AT	HOSPIRA	450MG/100ML		N018380	001		Aug	DISC
>D>	AT		450MG/100ML		N017670	001		Aug	DISC
>A>		@	450MG/100ML		N017670	001		Aug	DISC
>A>		@	450MG/100ML		N018380	001		Aug	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT

	AB +	SANOFI AVENTIS US	62.5MG/5ML		N020955	001	Feb 18, 1999	Mar	CFTG

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

	AB	GENERAMEDIX	62.5MG/5ML		A078215	001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F 18

		@ NIH NCI DCTD	10-200mCi/ML		N022494	001	Jan 26, 2011	Apr	DISC
	+		10-200mCi/ML		N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS
NITHIODOTE

	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)		N201444	001	Jan 14, 2011	Feb	CTNA

SODIUM NITRITE

	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)		N201444	001	Jan 14, 2011	Jan	NEWA

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	AA	PADDOCK LABS	15GM/60ML		A090590	001	May 13, 2011	May	NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

		@ PFIZER	EQ 2GM BASE/VIAL	N050347	001		Jun	DISC
		@	EQ 4GM BASE/VIAL	N050347	002		Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

		@ PFIZER	EQ 1GM BASE/2.5ML	A060111	001		Jul	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

>D>	+	KING PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Aug	CAHN
>A>	+	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Aug	CAHN

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Jun	CFTG

SUMATRIPTAN SUCCINATE

AB		SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	NEWA
>D> AP		TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009	Aug	DISC
>A>		@	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009	Aug	DISC
>D> AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009	Aug	DISC
>A>		@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009	Aug	DISC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

		@ ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
		@	EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
		@	EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

		@ SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993	Jun	DISC
		@	EQ 20MG BASE	N020070	002	Sep 09, 1993	Jun	DISC
		@	EQ 30MG BASE	N020070	003	Sep 09, 1993	Jun	DISC
		@	EQ 40MG BASE	N020070	004	Sep 09, 1993	Jun	DISC

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>A>	AB	ACCORD HLTHCARE	0.5MG	A091195	001	Aug 31, 2011	Aug	NEWA
>A>	AB		1MG	A091195	002	Aug 31, 2011	Aug	NEWA
>A>	AB		5MG	A091195	003	Aug 31, 2011	Aug	NEWA

TAPENTADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER

>A>		ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N200533	001	Aug 25, 2011	Aug	NEWA
>A>			EQ 100MG BASE	N200533	002	Aug 25, 2011	Aug	NEWA
>A>			EQ 150MG BASE	N200533	003	Aug 25, 2011	Aug	NEWA
>A>			EQ 200MG BASE	N200533	004	Aug 25, 2011	Aug	NEWA
>A>	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	Aug	NEWA

TELAPREVIR

TABLET; ORAL
INCIVEK

	+	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	May	NEWA

TELBIVUDINE

SOLUTION; ORAL
TYZEKA

	@	NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009	Jun	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB		JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
AB			EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
AB			EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
AB			EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB		MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
	@	ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

>A>		ABBOTT LABS	1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000	Aug	CAHN
>A>	BX	+	1% (5GM/PACKET)	N021015	002	Feb 28, 2000	Aug	CAHN
>D>	BX	+ ABBOTT PRODS	1% (5GM/PACKET)	N021015	002	Feb 28, 2000	Aug	CAHN
>D>			1% (2.5GM/PACKET)	N021015	001	Feb 28, 2000	Aug	CAHN

GEL, METERED; TRANSDERMAL
ANDROGEL

>A>	+	ABBOTT LABS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003	Aug	CAHN
>A>	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Aug	CAHN
>D>	+	ABBOTT PRODS	1% (1.25GM/ACTIVATION)	N021015	003	Sep 26, 2003	Aug	CAHN
>D>	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Aug	CAHN
	+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA

FORTESTA

	+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT

TABLET, EXTENDED RELEASE; BUCCAL
STRIANT
+ ACTIENT PHARMS 30MG N021543 001 Jun 19, 2003 Jun CAHN

TETRABENAZINE

TABLET; ORAL
XENAZINE
VALEANT INTL 12.5MG N021894 001 Aug 15, 2008 Jun CAHN
+ 25MG N021894 002 Aug 15, 2008 Jun CAHN

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
@ SCHIFF AND CO 12.7MG/FIBER N050653 001 Mar 25, 1994 Jun CAHN

SUSPENSION; ORAL
SUMYCIN
@ PAR PHARM 125MG/5ML A060400 001 Jul DISC

TABLET; ORAL
SUMYCIN
@ PAR PHARM 250MG A061147 001 Jul DISC
@ 500MG A061147 004 Jul DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEO-24
BC ACTIENT PHARMS 100MG A087942 001 Aug 22, 1983 Jun CAHN
BC 200MG A087943 001 Aug 22, 1983 Jun CAHN
BC 300MG A087944 001 Aug 22, 1983 Jun CAHN
400MG A081034 001 Feb 28, 1992 Jun CAHN

INJECTABLE; INJECTION
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
>D> AP + HOSPIRA 80MG/100ML N019211 002 Dec 14, 1984 Aug DISC
>A> @ 80MG/100ML N019211 002 Dec 14, 1984 Aug DISC
>D> AP + 200MG/100ML N019211 004 Dec 14, 1984 Aug DISC
>A> @ 200MG/100ML N019211 004 Dec 14, 1984 Aug DISC
>D> AP + 400MG/100ML N019211 005 Dec 14, 1984 Aug DISC
>A> @ 400MG/100ML N019211 005 Dec 14, 1984 Aug DISC

SOLUTION; ORAL
THEOPHYLLINE
+ SILARX 80MG/15ML A091156 001 Apr 13, 2011 Mar NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE
@ HOSPIRA 100MG/ML A040079 001 May 03, 1996 May DISC

TICAGRELOR

TABLET; ORAL
BRILINTA
+ ASTRAZENECA LP 90MG N022433 001 Jul 20, 2011 Jul NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE
>D> AB ACTAVIS ELIZABETH 250MG A075253 001 Aug 20, 1999 Aug DISC
>A> @ 250MG A075253 001 Aug 20, 1999 Aug DISC

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
>A>		@	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
>D>	AB		EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
>A>		@	EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
		@ ACTAVIS TOTOWA	EQ 2MG BASE	A076281	001	Oct 20, 2003	Jul	DISC
		@	EQ 4MG BASE	A076281	002	Oct 20, 2003	Jul	DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT	FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>	AP	HOSPIRA	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD
>D>	AP	+	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
>A>		@	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
>A>	AP	+	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD

TOLCAPONE

TABLET; ORAL
TASMAR

	+	VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998	Jun	CRLD
		@	200MG	N020697	002	Jan 29, 1998	Jun	DISC

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

>D>	AB	ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC
>A>		@	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613	002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613	003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613	004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
>A> CONZIP

>A> +	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010	Aug	CTNA
>A>		150MG	N022370	004	Aug 01, 2011	Aug	NEWA
>A>		200MG	N022370	002	May 07, 2010	Aug	CTNA
>A>		300MG	N022370	003	May 07, 2010	Aug	CTNA

>D> TRAMADOL HYDROCHLORIDE

>D> +	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010	Aug	CTNA
>D>		200MG	N022370	002	May 07, 2010	Aug	CTNA
>D>		300MG	N022370	003	May 07, 2010	Aug	CTNA

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

>D> AB	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002	Aug	DISC
>A> @		50MG	A075960	001	Jun 19, 2002	Aug	DISC
AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
TRAMADOL HYDROCHLORIDE

>A> AB	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Aug	NEWA
>A> AB		200MG	A200503	002	Aug 29, 2011	Aug	NEWA
>A> AB		300MG	A200503	003	Aug 29, 2011	Aug	NEWA

ULTRAM ER

AB +	VALEANT INTL	100MG	N021692	001	Sep 08, 2005	Jun	CAHN
AB		200MG	N021692	002	Sep 08, 2005	Jun	CAHN
>D> BC		300MG	N021692	003	Sep 08, 2005	Aug	CTEC
>A> AB		300MG	N021692	003	Sep 08, 2005	Aug	CTEC
BC		300MG	N021692	003	Sep 08, 2005	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE

>A> +	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Aug	CAHN
>D> +	VICTORY PHARMA	50MG	N021693	001	May 05, 2005	Aug	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION
CYKLOKAPRON

>D> +	PHARMACIA AND UPJOHN	100MG/ML	N019281	001	Dec 30, 1986	Aug	CFTG
>A> AP +		100MG/ML	N019281	001	Dec 30, 1986	Aug	CFTG

>A> TRANEXAMIC ACID

>A> AP	PHARMAFORCE	100MG/ML	A201885	001	Aug 10, 2011	Aug	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

@ ALCON		0.004%	N021257	001	Mar 16, 2001	May	DISC

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>D>		+	ANGELINI LABOPHARM	150MG	N022411	001	Feb 02, 2010	Aug	CAHN
		+		150MG	N022411	001	Feb 02, 2010	Jun	CAHN
>D>				300MG	N022411	002	Feb 02, 2010	Aug	CAHN
				300MG	N022411	002	Feb 02, 2010	May	CAHN
>A>		+	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	Aug	CAHN
>A>				300MG	N022411	002	Feb 02, 2010	Aug	CAHN

TRETINOIN

CREAM; TOPICAL

RENOVA

	+	ORTHO JANSSEN	0.02%	N021108	001	Aug 31, 2000	Jul	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jul	CAHN

RETIN-A

AB	+	ORTHO JANSSEN	0.025%	N019049	001	Sep 16, 1988	Jul	CAHN
AB1	+		0.05%	N017522	001		Jul	CAHN
AB	+		0.1%	N017340	001		Jul	CAHN

GEL; TOPICAL

RETIN-A

AB	+	ORTHO JANSSEN	0.01%	N017955	001		Jul	CAHN
AB	+		0.025%	N017579	002		Jul	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	ORTHO JANSSEN	0.05%	N016921	001		Jul	CAHN

SWAB; TOPICAL

RETIN-A

	@	ORTHO JANSSEN	0.05%	N016921	002		Jul	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT		ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982	Aug	DISC
>A>			@	0.1%	A087798	001	Jun 04, 1982	Aug	DISC

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT		ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982	Aug	DISC
>A>			@	0.1%	A087799	001	Jun 07, 1982	Aug	DISC

PASTE; DENTAL

>D> ORACORT

>D>	AT	+	TARO	0.1%	A070730	001	Oct 01, 1986	Aug	CTNA

>A> TRIAMCINOLONE ACETONIDE

>A>	AT	+	TARO	0.1%	A070730	001	Oct 01, 1986	Aug	CTNA

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

>D>	AB		BARR	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Aug	CAHN
>A>	AB		TEVA BRANDED PHARM	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Aug	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	May	CAHN
AP		PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011	May	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

URSODIOL

TABLET; ORAL
URSODIOL

AB	GLENMARK GENERICS	250MG	A090801	001	Jul 12, 2011	Jul	NEWA
AB		500MG	A090801	002	Jul 12, 2011	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	May	CAHN
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	May	CAHN
AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Jun	NEWA

VANDETANIB

TABLET; ORAL
VANDETANIB

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243	001	May 11, 2010	May	CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	May	CAHN

>A> VEMURAFENIB

>A> TABLET; ORAL
>A> ZELBORAF

>A> +	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011	Aug	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

	AB		AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011	Apr	NEWA
	AB			EQ 75MG BASE	A200834	002	Apr 14, 2011	Apr	NEWA
	AB			EQ 150MG BASE	A200834	003	Apr 14, 2011	Apr	NEWA
	AB		DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011	Apr	NEWA
	AB			EQ 75MG BASE	A078421	002	May 06, 2011	Apr	NEWA
	AB			EQ 150MG BASE	A078421	003	May 06, 2011	Apr	NEWA
	AB		MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	May	NEWA
	AB			EQ 75MG BASE	A078789	002	Jun 01, 2011	May	NEWA
	AB			EQ 150MG BASE	A078789	003	Jun 01, 2011	May	NEWA
	AB		ORCHID HLTHCARE	EQ 37.5MG BASE	A091123	001	Jul 11, 2011	Jun	NEWA
	AB			EQ 75MG BASE	A091123	002	Jul 11, 2011	Jun	NEWA
	AB			EQ 150MG BASE	A091123	003	Jul 11, 2011	Jun	NEWA
	AB		TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	May	NEWA
	AB			EQ 75MG BASE	A090899	002	Jun 01, 2011	May	NEWA
	AB			EQ 150MG BASE	A090899	003	Jun 01, 2011	May	NEWA
	AB		VALEANT INTL	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Apr	NEWA
	AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Apr	NEWA
	AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Apr	NEWA
	AB		WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Apr	NEWA
	AB			EQ 75MG BASE	A078865	002	Apr 14, 2011	Apr	NEWA
	AB			EQ 150MG BASE	A078865	003	Apr 14, 2011	Apr	NEWA
	AB		ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011	Apr	NEWA
	AB			EQ 75MG BASE	A090174	002	Apr 14, 2011	Apr	NEWA
	AB			EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

>D>			EFFEXOR						
>D>	AB		WYETH PHARMS INC	EQ 25MG BASE	N020151	002	Dec 28, 1993	Aug	DISC
>A>		@		EQ 25MG BASE	N020151	002	Dec 28, 1993	Aug	DISC
>D>	AB			EQ 37.5MG BASE	N020151	006	Dec 28, 1993	Aug	DISC
>A>		@		EQ 37.5MG BASE	N020151	006	Dec 28, 1993	Aug	DISC
>D>	AB	+		EQ 50MG BASE	N020151	003	Dec 28, 1993	Aug	DISC
>A>		@		EQ 50MG BASE	N020151	003	Dec 28, 1993	Aug	DISC
>D>	AB			EQ 75MG BASE	N020151	004	Dec 28, 1993	Aug	DISC
>A>		@		EQ 75MG BASE	N020151	004	Dec 28, 1993	Aug	DISC
>D>	AB			EQ 100MG BASE	N020151	005	Dec 28, 1993	Aug	DISC
>A>		@		EQ 100MG BASE	N020151	005	Dec 28, 1993	Aug	DISC
			VENLAFAXINE HYDROCHLORIDE						
	AB		ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932	001	Dec 14, 2010	Jul	CAHN
	AB			EQ 37.5MG BASE	A078932	002	Dec 14, 2010	Jul	CAHN
	AB			EQ 50MG BASE	A078932	003	Dec 14, 2010	Jul	CAHN
	AB			EQ 75MG BASE	A078932	004	Dec 14, 2010	Jul	CAHN
	AB			EQ 100MG BASE	A078932	005	Dec 14, 2010	Jul	CAHN
>D>	AB		PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008	Aug	DISC
>A>		@		EQ 25MG BASE	A078517	001	Jun 13, 2008	Aug	DISC
>D>	AB			EQ 37.5MG BASE	A078517	002	Jun 13, 2008	Aug	DISC
>A>		@		EQ 37.5MG BASE	A078517	002	Jun 13, 2008	Aug	DISC
>D>	AB			EQ 50MG BASE	A078517	003	Jun 13, 2008	Aug	DISC
>A>		@		EQ 50MG BASE	A078517	003	Jun 13, 2008	Aug	DISC
>D>	AB			EQ 75MG BASE	A078517	004	Jun 13, 2008	Aug	DISC
>A>		@		EQ 75MG BASE	A078517	004	Jun 13, 2008	Aug	DISC
>D>	AB			EQ 100MG BASE	A078517	005	Jun 13, 2008	Aug	DISC
>A>		@		EQ 100MG BASE	A078517	005	Jun 13, 2008	Aug	DISC

TABLET; ORAL
VENLAFAXINE HYDROCHLORIDE

>D>	AB	TEVA	EQ 50MG BASE	A076690	003	Aug 03, 2006	Aug	CRLD
>A>	AB	+	EQ 50MG BASE	A076690	003	Aug 03, 2006	Aug	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE

>D>	AP	HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987	Aug	DISC
>A>		@	2.5MG/ML	A070577	001	Feb 02, 1987	Aug	DISC

TABLET; ORAL
VERAPAMIL HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986	Aug	DISC
>A>		@	80MG	A071019	001	Sep 24, 1986	Aug	DISC
>D>	AB		120MG	A070468	001	Sep 24, 1986	Aug	DISC
>A>		@	120MG	A070468	001	Sep 24, 1986	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
VERAPAMIL HYDROCHLORIDE

	AB	GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Jul	NEWA
	AB		180MG	A090700	002	Aug 03, 2011	Jul	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

		FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	May	CAHN
			20MG	N022567	002	Jan 21, 2011	May	CAHN
	+		40MG	N022567	003	Jan 21, 2011	May	CAHN
		TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA
			20MG	N022567	002	Jan 21, 2011	Jan	NEWA
	+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

		@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

	AB	INVAGEN PHARMS	1MG	A090935	001	May 25, 2011	May	NEWA
	AB		2MG	A090935	002	May 25, 2011	May	NEWA
	AB		2.5MG	A090935	003	May 25, 2011	May	NEWA
	AB		3MG	A090935	004	May 25, 2011	May	NEWA
	AB		4MG	A090935	005	May 25, 2011	May	NEWA
	AB		5MG	A090935	006	May 25, 2011	May	NEWA
	AB		6MG	A090935	007	May 25, 2011	May	NEWA
	AB		7.5MG	A090935	008	May 25, 2011	May	NEWA
	AB		10MG	A090935	009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

	AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN

TABLET; ORAL
ZIDOVUDINE

		@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Jun	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	Apr	NEWA
AB	SANDOZ	6.25MG	A090107	001	Jul 01, 2011	Jun	NEWA
AB		12.5MG	A090107	002	Jul 01, 2011	Jun	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	NEWA
AB		12.5MG	A078483	002	Jun 06, 2011	Jul	NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>		ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008	Aug	DISC
>A>	@		5MG/5ML	A090378	002	May 09, 2008	Aug	DISC
		SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
		TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>		ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008	Aug	DISC
>A>	@		5MG/5ML	A090378	001	May 09, 2008	Aug	DISC
		SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
		TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>		SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011	Aug	NEWA
>A>			10MG	A090142	002	Aug 30, 2011	Aug	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>		SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011	Aug	NEWA
>A>			10MG	A090142	004	Aug 30, 2011	Aug	NEWA

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

PHARMASEAL SCRUB CARE

>A>	+	CAREFUSION	4%	N019793	001	Dec 02, 1988	Aug	CAHN
>D>	+	PHARMASEAL	4%	N019793	001	Dec 02, 1988	Aug	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

	+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN

CHLORAPREP SINGLE SWABSTICK

	+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN

CHLORAPREP TRIPLE SWABSTICK

	+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

>D>		ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC
>A>	@		5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

		MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

	+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

	+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL

ALLEGRA ALLERGY

	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
	MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	NEWA
	TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
	MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	NEWA
	TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
		180MG	A076502	008	Apr 12, 2011	Mar	NEWA
	MYLAN	60MG	A077081	006	Jul 21, 2011	Jul	NEWA
		180MG	A077081	008	Jul 21, 2011	Jul	NEWA
	TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
		180MG	A076447	008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
		180MG	A076502	009	Apr 12, 2011	Mar	NEWA
	MYLAN	60MG	A077081	007	Jul 21, 2011	Jul	NEWA
		180MG	A077081	009	Jul 21, 2011	Jul	NEWA
	TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
		180MG	A076447	009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011	Jun	NEWA

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

>A>	AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Aug	NEWA

TABLET; ORAL

IBUPROFEN

>D>	ADVENT PHARMS	200MG	A076460	001	Nov 26, 2003	Aug	CAHN
		200MG	A076460	001	Nov 26, 2003	Jul	CAHN

TABLET; ORAL
IBUPROFEN

>A>	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	Aug	CAHN
		200MG	A076460	001	Nov 26, 2003	May	CAHN
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
		200MG	A091239	001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
	SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
		200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL
PLAN B

+	TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL
LOPERAMIDE HYDROCHLORIDE

	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	May	NEWA

LORATADINE

TABLET; ORAL
LORATADINE

>A>	MYLAN	10MG	A078447	001	Aug 12, 2011	Aug	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK

>D>	ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997	Aug	DISC
>A>	@	2%,100MG	A074586	001	Jul 17, 1997	Aug	DISC

MINOXIDIL

AEROSOL, FOAM; TOPICAL
MINOXIDIL

	PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Apr	NEWA

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

	MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA
	RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	May	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX

	PERRIGO R AND D	EQ 2MG BASE	A091349	001	Jul 20, 2011	Jul	NEWA
		EQ 4MG BASE	A091354	001	Jul 20, 2011	Jul	NEWA

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

>A>	+	BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000	Aug	CAHN
>D>	+	PFIZER	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000	Aug	CAHN

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

		ANBEX	65MG	N018664	002	May 12, 2011	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

		MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN
		PERRIGO R AND D	EQ 150MG BASE	A091429	002	May 11, 2011	Apr	NEWA
			EQ 150MG BASE	A091429	001	May 11, 2011	Apr	NEWA
		SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jun	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2011

NO AUGUST 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE - ZYTIGA							
N202379	001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
ADAPALENE - DIFFERIN							
N021753	001	7868044	Mar 12, 2023	U-1078			
ADAPALENE - DIFFERIN							
N022502	001	>A> 7998467	May 31, 2028	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N022320	001	7964202	Sep 01, 2024	DP U-1078			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG							
N021775	001	5250542	Mar 29, 2016	DS DP U-878			
AMBRISENTAN - LETAIRIS							
N022081	001	RE42462	Oct 07, 2015	DS			
AMBRISENTAN - LETAIRIS							
N022081	002	RE42462	Oct 07, 2015	DS			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10							
N021303	001	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N022434 001	7589106	Sep 27, 2026	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
ARIPIPRAZOLE - ABILIFY						
N021436 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX						
N050797 001	7887844	Feb 14, 2024	DP			
AZTREONAM - CAYSTON						
N050814 001					**>A>** ODE	Feb 22, 2017
BIMATOPROST - LATISSE						
N022369 001	**>A>** 8017655	Nov 27, 2012	DS DP			
BIMATOPROST - LUMIGAN						
N021275 001	**>A>** 8017655	Nov 27, 2012	DS DP			
BIMATOPROST - LUMIGAN						
N022184 001	**>A>** 8017655	Nov 27, 2012	DS DP			
BIVALIRUDIN - ANGIOMAX						
N020873 001	**>A>** 5196404	Aug 13, 2012	DS DP U-1040			
	>A> 5196404*PED	Feb 13, 2013				
BOCEPREVIR - VICTRELIS						
N202258 001	7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 001	7967011	Aug 11, 2021	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 002	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
CARBAMAZEPINE - CARBATROL						
N020712 001	5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL						
N020712 002	5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL						
N020712 003	5326570	Jul 23, 2011	U-215			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CELECOXIB - CELEBREX						
N020998 001	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 002	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 003	5760068	Jun 02, 2015	U-672			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS						
N021441 001	7863287	Feb 28, 2027	DP			
CICLOPIROX - LOPROX						
N021159 001	7981909	Sep 16, 2017	U-1162			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
					M-101	Feb 25, 2014
					ODE	Feb 25, 2018
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
COLCHICINE - COLCRYS						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Feb 17, 2029	U-1161			
	7981938	Oct 06, 2028	U-1166			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRIZOTINIB - XALKORI						
N202570 001	**>A>** 7230098	Feb 01, 2025	DS		**>A>** NCE	Aug 26, 2016
	>A> 7825137	May 12, 2027	U-1179			
	>A> 7858643	Oct 08, 2029	DS DP			
CRIZOTINIB - XALKORI						
N202570 002	**>A>** 7230098	Feb 01, 2025	DS		**>A>** NCE	Aug 26, 2016
	>A> 7825137	May 12, 2027	U-1179			
	>A> 7858643	Oct 08, 2029	DS DP			
CYANOCOBALAMIN - NASCOBAL						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N022512 001	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N022512 002	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-744		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-935		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-903		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-935			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DASATINIB - SPRYCEL						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
DASATINIB - SPRYCEL						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
DICLOFENAC SODIUM - SOLARAZE						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
DORIPENEM - DORIBAX						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
DORIPENEM - DORIBAX						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 001	7915307	Aug 24, 2027	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 002	7915307	Aug 24, 2027	U-620			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N022425 001	5223510	Jul 26, 2012	DS DP U-992			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N021937 001	**>A>** 5922695	Jul 25, 2017	DS		U-750	
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP		U-750	
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP		U-750	
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017			U-750	
	>A> 6043230*PED	Jan 25, 2018				
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 001	7547719	Jul 13, 2025	DS DP		U-930	
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 002	7547719	Jul 13, 2025	DS DP		U-930	
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 003	7547719	Jul 13, 2025	DS DP		U-930	
EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N202123 001	**>A>** 5814639	Sep 29, 2015	DS DP			
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 5922695	Jul 25, 2017	DS		U-257	
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP		U-257	
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP			
	>A> 5977089*PED	Jan 25, 2018			U-257	
	>A> 6043230	Jul 25, 2017			U-257	
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020			U-257	
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
	>A> 6838464	Feb 26, 2021	DS DP			
	>A> 7067522	Dec 20, 2019	DS DP			
	>A> 7125879	Apr 14, 2023	DS DP		U-257	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N021752 001	**>A>** 5922695	Jul 25, 2017	DS U-248			
	>A> 5922695	Jul 25, 2017	DS U-541			
	>A> 5922695	Jul 25, 2017	DS U-1170			
	>A> 5922695*PED	Jan 25, 2018				
	>A> 5935946	Jul 25, 2017	DS DP U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-248			
	>A> 5935946	Jul 25, 2017	DS DP U-541			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-541			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-1170			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	DP U-1170			
	>A> 6043230	Jul 25, 2017	DP U-248			
	>A> 6043230	Jul 25, 2017	DP U-541			
	>A> 6043230*PED	Jan 25, 2018				
	>A> 6642245	Nov 04, 2020	U-541			
	>A> 6642245	Nov 04, 2020	U-1170			
	>A> 6642245	Nov 04, 2020	U-248			
EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE						
A090870 001					PC	Oct 29, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 001					NPP	Feb 27, 2011
					PED	Aug 27, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 002					NPP	Feb 27, 2011
					PED	Aug 27, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N022101 001					M-86	Jun 18, 2012
					PED	Dec 18, 2012
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N022511 002		5714504	Feb 03, 2015	DP U-1053			
		5714504*PED	Aug 03, 2015				
		5900424	May 04, 2016	DS U-1053			
		5900424*PED	Nov 04, 2016				
		6369085	May 25, 2018	DS DP U-1053			
		6369085*PED	Nov 25, 2018				
		6875872	May 27, 2014	DS			
		6875872*PED	Nov 27, 2014				
		7411070	May 25, 2018	DS U-1053			
		7411070*PED	Nov 25, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N022262 001		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N021840 001		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
N022573 001		5552394	Jul 22, 2014	U-828			
		6667050	Apr 06, 2019	DP U-828			
ETRAVIRINE - INTELENCE							
N022187 001	>A>	7037917	Dec 13, 2020	DS DP U-256			
	>A>	7037917	Dec 13, 2020	DS DP U-1016			
		7887845	Mar 25, 2019	DP			
ETRAVIRINE - INTELENCE							
N022187 002		6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	>A>	7037917	Dec 13, 2020	DS DP U-1016			
		7887845	Mar 25, 2019	DP			
EVEROLIMUS - AFINITOR							
N022334 001		5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
						ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR							
N022334 002		5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
						ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR							
N022334 003		5665772	Sep 09, 2019			I-638	May 05, 2014
						NCE	Mar 30, 2014
						ODE	Oct 29, 2017
EVEROLIMUS - ZORTRESS							
N021560 001		5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS							
N021560 002		5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS							
N021560 003		5665772	Sep 09, 2019	DS DP U-1049			
EXENATIDE SYNTHETIC - BYETTA							
N021773 001		5424286	Dec 01, 2016	U-653			
		5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA							
N021773	002	5424286	Dec 01, 2016	U-653			
		5424286	Dec 01, 2016	U-1108			
EZETIMIBE - ZETIA							
N021445	001	**>A>** 5846966	Sep 21, 2013	U-474			
		>A> 5846966	Sep 21, 2013	U-473			
		>A> 5846966	Sep 21, 2013	U-1172			
		>A> 7612058	Jan 25, 2022	U-1173			
		>A> 7612058	Jan 25, 2022	U-1027			
		>A> RE42461	Oct 25, 2016	DS DP U-473			
		>A> RE42461	Oct 25, 2016	DS DP U-1173			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	001	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	002	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	003	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN							
N021687	004	RE37721	Oct 25, 2016	DS DP U-473	Y		
		RE37721*PED	Apr 25, 2017		Y		
		RE42461	Oct 25, 2016	DS DP U-473			
		RE42461*PED	Apr 25, 2017				
EZOGABINE - POTIGA							
N022345	001					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	002					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	003					NCE	Jun 10, 2016
EZOGABINE - POTIGA							
N022345	004					NCE	Jun 10, 2016
FAMCICLOVIR - FAMVIR							
N020363	001					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363	002					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363	003					M-98	Jan 31, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FAMOTIDINE; IBUPROFEN - DUEXIS						
N022519 001					NC	Apr 23, 2014
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRIC ACID - FIBRICOR						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENOFIBRIC ACID - FIBRICOR						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENTANYL CITRATE - ABSTRAL						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - FENTORA						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - FENTORA						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - LAZANDA						
N022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
FENTANYL CITRATE - LAZANDA						
N022569 002					NDF	Jun 30, 2014
FERUMOXYTOL - FERAHEME						
N022180 001	7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
	>A> 7985772	May 11, 2019	DS DP U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
	>A> 7985772	May 11, 2019	DS DP U-913			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N021909 003	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N201373 002	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION							
N020786 002		5578610	Nov 26, 2013	DS DP U-1159			
		5578610*PED	May 26, 2014				
		5855912	Feb 28, 2015	DP			
		5855912*PED	Aug 28, 2015				
		6037353	Mar 14, 2017	U-1159			
		6037353*PED	Sep 14, 2017	U-138			
		6039974	Jul 31, 2018	DP			
		6113942	Feb 28, 2015	DP			
		6113942*PED	Aug 28, 2015				
		6187791	May 11, 2012	U-1159			
		6187791*PED	Nov 11, 2012	U-138			
		6399632	May 11, 2012	U-1159			
		6399632*PED	Nov 11, 2012	U-468			
		7135571	May 18, 2014	DS U-1159			
		7135571*PED	Nov 18, 2014				
		7138524	May 18, 2014	DS			
		7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION							
N021704 002		5578610	Nov 26, 2013	DS DP U-1159			
		5578610*PED	May 26, 2014				
		6037353	Mar 14, 2017	U-1159			
		6037353*PED	Sep 14, 2017				
		6187791	May 11, 2012	U-1159			
		6187791*PED	Nov 11, 2012				
		6399632	May 11, 2012	U-1159			
		6399632*PED	Nov 11, 2012				
		6613357	Dec 25, 2020	DP U-1159			
		7138524	May 18, 2014	DS			
		7138524*PED	Nov 18, 2014				
		RE39069	May 29, 2018	DP			
FIDAXOMICIN - DIFICID							
N201699 001	**>A>**	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	>A>	7863249	Jul 31, 2027	DS DP			
	>A>	7906489	Mar 04, 2027	U-319			
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA							
N021112 001		7915243	Mar 22, 2026	DP			
		7939516	May 04, 2025	DP			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ							
N021211 001						**>A>** D-133	Aug 22, 2014
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ							
N021211 002						**>A>** D-133	Aug 22, 2014
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ							
N021211 003						**>A>** D-133	Aug 22, 2014
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ							
N021211 004						**>A>** D-133	Aug 22, 2014
FOSAPREPITANT DIMEGLUMINE - EMEND							
N022023 001	**>A>**	5691336	Mar 04, 2019	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSAPREPITANT DIMEGLUMINE - EMEND						
N022023 002	**>A>** 5691336	Mar 04, 2019	DS DP			
FULVESTRANT - FASLODEX						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
GABAPENTIN - GABAPENTIN						
A078974 001					PC	Aug 22, 2011
GABAPENTIN - GRALISE						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
GABAPENTIN - GRALISE						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
GADOBUTROL - GADAVIST						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 001					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 002					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A079183 001					PC	May 14, 2011
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 001					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 002					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 003					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 004					M-102	Apr 29, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					I-635	Feb 25, 2014
HYDROCORTISONE BUTYRATE - LOCOID						
N022076 001	**>A>** 7981877	Jan 23, 2025	DP			
HYDROXOCOBALAMIN - CYANOKIT						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					ODE	Feb 03, 2018
IBUPROFEN LYSINE - NEOPROFEN						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
ICATIBANT ACETATE - FIRAZYR						
N022150 001					**>A>** NCE	Aug 25, 2016
ILOPERIDONE - FANAPT						
N022192 001	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 002	**>A>** RE39198	Nov 15, 2016	DS DP U-971			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N022192 003	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 004	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 005	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 006	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N022192 007	**>A>** RE39198	Nov 15, 2016	DS DP U-971			
IMIQUIMOD - ZYCLARA						
N022483 001					I-636	Mar 24, 2014
IMIQUIMOD - ZYCLARA						
N022483 002					NS	Jul 15, 2014
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015	U-1125			
	5776894	Jul 07, 2015	DS DP			
INSULIN GLARGINE RECOMBINANT - LANTUS						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N021629 003	7918833	Sep 23, 2027	DP			
INSULIN RECOMBINANT HUMAN - HUMULIN R						
N018780 001					NR	Mar 25, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R PEN						
N018780 005					NR	Mar 25, 2014
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016
IXABEPILONE - IXEMPRA KIT						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
LAMOTRIGINE - LAMICTAL ODT						
N022251 001	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 002	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 003	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 004	7919115	Jan 04, 2029	DS DP			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LENALIDOMIDE - REVLIMID						
N021880 003	7968569	Oct 07, 2023	U-1165			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 007	**>A>** 5575987	Sep 02, 2013	DP		**>A>** NP	Aug 15, 2014
	>A> 5631020	May 20, 2014	DP			
	>A> 5716640	Sep 02, 2013	DP			
	>A> 6036976	Dec 13, 2016	DP			
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N020263 008	**>A>** 5480656	Jan 02, 2013	DP		**>A>** NP	Aug 15, 2014
	>A> 5575987	Sep 02, 2013	DP			
	>A> 5631020	May 20, 2014	DP			
	>A> 5643607	Jul 01, 2013	DP			
	>A> 5716640	Sep 02, 2013	DP			
	>A> 6036976	Dec 13, 2016	DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 001					I-637	Apr 29, 2014
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Mar 07, 2015
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Mar 07, 2015
LINAGLIPTIN - TRADJENTA						
N201280 001	6303661	Apr 24, 2017	U-774		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
LOTEPREDNOL ETABONATE - LOTEMAX						
N200738 001					NDF	Apr 15, 2014
					PED	Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			
LOVASTATIN; NIACIN - ADVICOR						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			
LOVASTATIN; NIACIN - ADVICOR						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	>A> 7998506	Sep 20, 2013	U-1137			
	>A> 7998506	Sep 20, 2013	U-1135			
	>A> 7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MALATHION - OVIDE						
N018613 001	7977324	Aug 14, 2026	DP			
MESALAMINE - LIALDA						
N022000 001					I-640	Jul 14, 2014
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 001	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 002	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
METRONIDAZOLE - VANDAZOLE						
N021806 001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 001	7888342	Nov 05, 2021	U-882			
>A>	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	7888342	Nov 05, 2021	U-882			
>A>	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	7888342	Nov 05, 2021	U-882			
>A>	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	7888342	Nov 05, 2021	U-882			
>A>	7994220	Sep 19, 2029	U-819			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 001	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	7919483	Feb 28, 2027	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	7919483	Feb 28, 2027	U-1078			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N022428 001	7671070*PED	Mar 29, 2020				
MUPIROCIN CALCIUM - BACTROBAN						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
NALTREXONE - VIVITROL						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
NEVIRAPINE - VIRAMUNE XR						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
NIACIN - NIASPAN						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
>A>	7998506	Sep 20, 2013	U-1141			
>A>	7998506	Sep 20, 2013	U-1138			
>A>	7998506	Sep 20, 2013	U-1139			
>A>	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	>A> 7998506	Sep 20, 2013	U-1141			
	>A> 7998506	Sep 20, 2013	U-1138			
	>A> 7998506	Sep 20, 2013	U-1139			
	>A> 7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	>A> 7998506	Sep 20, 2013	U-1141			
	>A> 7998506	Sep 20, 2013	U-1138			
	>A> 7998506	Sep 20, 2013	U-1139			
	>A> 7998506	Sep 20, 2013	U-1140			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 001	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 002	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 003	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	>A> 7998506	Sep 20, 2013	U-1151			
	>A> 7998506	Sep 20, 2013	U-1150			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N022068 002					**>A>** I-627	Jun 17, 2014
					>A> NCE	Oct 29, 2012
					>A> ODE	Oct 29, 2014
NITROGLYCERIN - RECTIV						
N021359 001					NP	Jun 21, 2014
OLANZAPINE - ZYPREXA ZYDIS						
N021086 001					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 002					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 003					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 004					NPP	Dec 04, 2012
					PED	Jun 04, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLOPATADINE HYDROCHLORIDE - PATANASE						
N021861 001	7977376	Feb 02, 2023	DP			
	7977376*PED	Aug 02, 2023	DP			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OXYCODONE HYDROCHLORIDE - OXECTA						
N202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	>A> 7981439	Nov 26, 2023	DP			
OXYCODONE HYDROCHLORIDE - OXECTA						
N202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	>A> 7981439	Nov 26, 2023	DP			
PACLITAXEL - ABRAXANE						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
PALIPERIDONE - INVEGA						
N021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 003					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 006					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	7960424	Jan 30, 2024	DP			
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE						
A091427 001					PC	Nov 01, 2011
PEMETREXED DISODIUM - ALIMTA						
N021462 001					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PEMETREXED DISODIUM - ALIMTA						
N021462 002					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PERFLUTREN - DEFINITY						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N202088 001	6149938	Jul 23, 2018	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N202088 002	6149938	Jul 23, 2018	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 001	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 002	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 003	6207661	Feb 22, 2019	DP			
	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLERIXAFOR - MOZOBIL						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 001					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 002					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 003					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 005					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 006					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N020667 007					M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 006	7695734	Apr 26, 2028	DP		I-623	Mar 19, 2013
					NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N022421 007	7695734	Apr 26, 2028	DP		I-623	Mar 19, 2013
					NDF	Feb 19, 2013
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001	7169780	Oct 03, 2023	DS DP			
RANOLAZINE - RANEXA						
N021526 001	6369062	May 27, 2019	DP	Y		
RETAPAMULIN - ALTABAX						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
RIBAVIRIN - COPEGUS						
N021511 001					**>A>** NPP	Aug 09, 2014
RIFAXIMIN - XIFAXAN						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
RIFAXIMIN - XIFAXAN						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N022406 001	7157456	Feb 08, 2021	DS DP		**>A>** NCE	Jul 01, 2016
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
RIZATRIPTAN BENZOATE - MAXALT						
N020864 001	5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT						
N020864 002	5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
ROFLUMILAST - DALIRESP						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
ROMIDEPSIN - ISTODAX						
N022393 001	4977138	Jul 06, 2012	DS DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 001	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 002	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 003	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 004	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 005	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 006	7927624	Dec 02, 2021	DP U-20			
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 002	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 003	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 004	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROSUVASTATIN CALCIUM - CRESTOR						
N021366 005	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
ROTIGOTINE - NEUPRO						
N021829 001	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO						
N021829 002	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO						
N021829 003	6699498	Nov 27, 2020	DP			
RUFINAMIDE - BANZEL						
N021911 001	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N021911 002	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N021911 003	6740669	Nov 14, 2022	DS DP			
RUFINAMIDE - BANZEL						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N022181 001	7947681	Nov 17, 2024	U-1156			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 001	7951400	Nov 30, 2028	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 002	7951400	Nov 30, 2028	DP			
SEVELAMER CARBONATE - RENVELA						
N022127 001 **>A>**	7985418	Oct 27, 2025	DP			
SINECATECHINS - VEREGEN						
N021902 001	7858662	Oct 02, 2026	DP U-172			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N201444 001					ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
SORAFENIB TOSYLATE - NEXAVAR						
N021923 001	7897623	Jan 12, 2020	DP			
SPINOSAD - NATROBA						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
SUNITINIB MALATE - SUTENT						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 001	**>A>** 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 002	**>A>** 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N022304 003	**>A>** 7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 001	**>A>** 7994364	Jun 27, 2025	DS DP U-1178		**>A>** NDF **>A>** NCE	Aug 25, 2014 Nov 20, 2013
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	**>A>** 7994364	Jun 27, 2025	DS DP U-1178		**>A>** NDF **>A>** NCE	Aug 25, 2014 Nov 20, 2013
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	**>A>** 7994364	Jun 27, 2025	DS DP U-1178		**>A>** NDF **>A>** NCE	Aug 25, 2014 Nov 20, 2013
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	**>A>** 7994364	Jun 27, 2025	DS DP U-1178		**>A>** NDF **>A>** NCE	Aug 25, 2014 Nov 20, 2013
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	**>A>** 7994364	Jun 27, 2025	DS DP U-1178		**>A>** NDF **>A>** NCE	Aug 25, 2014 Nov 20, 2013
TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3						
N019882 001	5573748	Nov 12, 2013	DP			
TELAPREVIR - INCIVEK						
N201917 001					NCE	May 23, 2016
TELBIVUDINE - TYZEKA						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
TELMISARTAN - MICARDIS						
N020850 002	**>A>** 7998953	Jun 06, 2020	U-1177			
	>A> 8003679	Oct 06, 2022	U-1176			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001	**>A>** 5922695	Jul 25, 2017	DS U-250		**>A>** I-569	Aug 11, 2011
	>A> 5922695	Jul 25, 2017	DS U-256		**>A>** M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-999		**>A>** NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		**>A>** ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			**>A>** PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		**>A>** PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-248		**>A>** PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-250		**>A>** PED	Feb 11, 2012
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				
TESTOSTERONE - ANDROGEL						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
TESTOSTERONE - FORTESTA						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
TESTOSTERONE - TESTIM						
N021454 001	7935690	Apr 21, 2023	U-1009			
THALIDOMIDE - THALOMID						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID							
N020785 003		7874984	Aug 28, 2018	U-733			
		7874984	Aug 28, 2018	U-732			
		7874984	Aug 28, 2018	U-442			
		7874984	Aug 28, 2018	U-371			
		7874984	Aug 28, 2018	U-1109			
		7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID							
N020785 004		7874984	Aug 28, 2018	U-733			
		7874984	Aug 28, 2018	U-732			
		7874984	Aug 28, 2018	U-442			
		7874984	Aug 28, 2018	U-371			
		7874984	Aug 28, 2018	U-1109			
		7959566	Oct 23, 2020	U-1155			
TICAGRELOR - BRILINTA							
N022433 001	**>A>**	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	>A>	6525060	Dec 02, 2019	DS DP U-1171			
	>A>	7250419	Dec 02, 2019	DS DP U-1171			
	>A>	7265124	Jul 09, 2021	DS DP U-1171			
TIGECYCLINE - TYGACIL							
N021821 001		7879828	Feb 05, 2029	DP			
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA							
N021395 001		6908928	Sep 24, 2021	DS DP U-762			
		6908928	Sep 24, 2021	DS DP U-566			
		7309707	Sep 24, 2021	DS DP			
		7694676	Mar 12, 2027	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT							
N021745 001	**>A>**	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT							
N021745 002	**>A>**	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT							
N021745 003	**>A>**	7988998	Oct 27, 2023	DP			
TRANEXAMIC ACID - LYSTEDA							
N022430 001		7947739	Mar 04, 2025	DP			
TREPROSTINIL SODIUM - REMODULIN							
N021272 001	**>A>**	7999007	Mar 29, 2029	DP U-1174			
TREPROSTINIL SODIUM - REMODULIN							
N021272 002	**>A>**	7999007	Mar 29, 2029	DP U-1174			
TREPROSTINIL SODIUM - REMODULIN							
N021272 003	**>A>**	7999007	Mar 29, 2029	DP U-1174			
TREPROSTINIL SODIUM - REMODULIN							
N021272 004	**>A>**	7999007	Mar 29, 2029	DP U-1174			
TRIAMCINOLONE ACETONIDE - NASACORT AQ							
N020468 001	**>A>**	7977045	Jul 03, 2016	DP U-896			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANDETANIB - VANDETANIB						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VANDETANIB - VANDETANIB						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VARENICLINE TARTRATE - CHANTIX						
N021928 001					M-105	Jul 22, 2014
VARENICLINE TARTRATE - CHANTIX						
N021928 002					M-105	Jul 22, 2014
VEMURAFENIB - ZELBORAF						
N202429 001	**>A>** 7504509	Oct 22, 2026	DS DP		**>A>** NCE	Aug 17, 2016
	>A> 7863288	Jun 20, 2029	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
ZOLEDRONIC ACID - RECLAST						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
ZOLEDRONIC ACID - ZOMETA						
N021223 003	**>A>** 4939130	Sep 02, 2012	DS DP U-53			
	>A> 4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028	DP			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm